Page last updated: 2024-12-05

troglitazone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5591
CHEMBL ID3542292
CHEBI ID9753
SCHEMBL ID4959

Synonyms (114)

Synonym
BRD-A13084692-001-02-5
gtpl2693
5-[[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
prelay
troglitazonum
noscal
ci-991
troglitazona
cs-045 ,
CHEBI:9753 ,
romozin
gr-92132x
5-{4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2h-chromen-2-yl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione
5-[(4-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2h-chromen-2-yl)methyl]oxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione
troglitazone, >=98% (hplc)
HSCI1_000037
(+-)-all-rac-5-(p-((6-hydroxy-2,5,7,8-tetramethyl-2-chromanyl)methoxy)benzyl)-2,4-thiazolidinedione
gr 92132x
ccris 8969
romglizone
cs 045
2,4-thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2h-1-benzopyran-2-yl)methoxy]phenyl]methyl]- (9ci)
97322-87-7
2,4-thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2h-1-benzopyran-2-yl)methoxy]phenyl]methyl]-
troglitazone
ci 991
5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2h-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione
rezulin
(+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione
5-(4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione
UPCMLD-DP017:001
UPCMLD-DP017
DB00197
NCGC00161599-03
troglitazone (jan/usan/inn)
rezulin (tn)
D00395
SPECTRUM5_001973
UPCMLD-DP017:002
NCGC00161599-01
NCGC00161599-02
NCGC00164445-01
2,4-thiazolidinedione, 5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2h-1-benzopyran-2-yl)methoxy)phenyl)methyl)-
c24h27no5s
brn 4338399
SMP2_000224
HMS2089D22
HMS2093D04
chembl3542292
5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy)benzyl)thiazolidine-2,4-dione
bdbm50101974
bdbm50088494
AKOS000281116
gr92132x
5-[[4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
A845704
NCGC00161599-06
NCGC00161599-05
NCGC00161599-07
NCGC00161599-04
unii-i66zz0zn0e
i66zz0zn0e ,
troglitazone [usan:inn:ban]
NCGC00254440-01
dtxsid8023719 ,
dtxcid603719
tox21_112119
tox21_300470
cas-97322-87-7
FT-0630994
NCGC00161599-11
NCGC00161599-08
S8432
CCG-208125
HY-50935
CS-1634
smr001550129
MLS006010817
T3920
(5r)-5-[[4-[[(2s)-6-hydroxy-2,5,7,8-tetramethyl-chroman-2-yl]methoxy]phenyl]methyl]thiazolidine-2,4-dione
SCHEMBL4959
tox21_112119_1
NCGC00161599-09
AB00643330-02
5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
5-{4-(6-hydroxy-2, 5, 7, 8-tetramethylchroman-2-yl-methoxy) benzyl) thiazolidine-2,4-dione
5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]thiazolidine -2,4-dione
5-[4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl]-2,4-dioxothiazolidine
5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2h-1- benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazlidinedione
5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7 ,8-tetramethyl-2h-1-benzopyran-2-yl)methoxy]phenyl ]methyl]-2,4-thiazolidinedione
HB2559
AC-31453
AKOS024457434
HMS3649G12
sr-05000000454
SR-05000000454-3
SR-05000000454-2
HMS3713D08
BCP06753
troglitazone - cas 97322-87-7
cs045
troglitazone (cs-045)
SR-05000000454-5
Q7844989
H12073
AS-56378
EX-A3782
a10bg01
5-(4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)-1,3-thiazolidine-2,4-dione
5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione)-t
5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy)benzyl)-2,4-thiazolidinedione
5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2h-1-benzopyran-2-yl)methoxy)phenyl)methyl)-2,4-thiazolidinedione
troglitazone (mart.)
5-(4-((6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2h-chromen-2-yl)methoxy)benzyl)-1,3-thiazolidine-2,4-dione

Research Excerpts

Overview

Troglitazone is a thiazolidinedione insulin sensitizer drug for the treatment of type 2 non-insulin-dependent diabetes mellitus (NIDDM) It is metabolized mainly to a sulfate conjugate (M-1) in humans.

ExcerptReferenceRelevance
"Troglitazone is a thiazolidinedione insulin sensitizer drug for the treatment of type 2 non-insulin-dependent diabetes mellitus (NIDDM). "( Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt
Funk, C; Gasser, R; Jehle, L; Lazendic, M; Pantze, M; Ponelle, C; Scheuermann, G, 2001
)
3.2
"Troglitazone is a thiazolidinedione insulin sensitizer drug that is metabolized mainly to a sulfate conjugate (M-1) in humans. "( Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity.
Goto, A; Nakajima, M; Nezu, J; Nozawa, T; Sugiura, S; Tamai, I; Tsuji, A; Yokoi, T, 2004
)
2
"Troglitazone (TGZ) is a peroxisome proliferator-activated receptor gamma agonist that could inhibit the expression of CD73."( CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms.
Gao, S; Hao, J; Huang, C; Li, X; Liu, J; Liu, W; Ma, Y; Wang, H; Wang, X; Wang, Z; Wu, L; Yang, S; Yu, X; Zhao, T, 2021
)
1.34
"Troglitazone (TGZ) is a peroxisome proliferator-activated receptor gamma (PPARγ) agonist that has been investigated as a potential chemopreventive and chemotherapeutic agent. "( In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer.
Fujita, M; Hasegawa, A; Okamura, N; Yamamori, M, 2017
)
2.17
"Troglitazone (TZ) is a synthetic ligand of peroxisome proliferator-activated receptor-γ, and it can induce apoptosis and autophagy in a variety of cancer cells."( The PPARγ agonist Troglitazone induces autophagy, apoptosis and necroptosis in bladder cancer cells.
Chen, T; Jiang, X; Xi, Z; Yan, S; Yang, X, 2014
)
1.46
"Troglitazone (TGZ) is an orally active hypoglycemic agent which is used for the treatment of non-insulin-dependent diabetes mellitus. "( Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity.
Chan, EC; Chui, WK; Ho, HK; New, LS; Saha, S, 2010
)
2.05
"Troglitazone (TGZ) is a synthetic thiazolidinedione drug belonging to a group of potent peroxisome proliferator-activated receptor gamma (PPAR gamma) agonists known to inhibit proliferation, alter cell cycle regulation, and induce apoptosis in various cancer cell types. "( The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells.
Chang, HY; Cheng, AL; Chuang, SE; Lai, GM; Yan, KH; Yao, CJ, 2010
)
2.08
"Troglitazone is a synthetic ligand of peroxisome proliferators activated receptor-gamma (PPARgamma) and induces apoptosis in a variety of malignant cells. "( Autophagy augmented by troglitazone is independent of EGFR transactivation and correlated with AMP-activated protein kinase signaling.
Guo, Y; Jiang, X; Sun, L; Wang, G; Xi, Z; Yan, J; Yang, H; Zhou, Y, 2010
)
2.11
"Troglitazone is an anti-diabetic agent that improves hyperglycemia by reducing peripheral insulin resistance in type II diabetic patients. "( Identification of troglitazone responsive genes: induction of RTP801 during troglitazone-induced apoptosis in Hep 3B cells.
Hong, SH; Kim, JC; Kim, JO; Kim, JY; Kim, MK; Kwack, MH; Sung, YK, 2010
)
2.14
"Troglitazone is a ligand for the peroxisome proliferator activated receptor gamma (PPARγ) that decreases growth of human prostate cancer cells in vitro and in vivo. "( Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism.
Akinyeke, TO; Stewart, LV, 2011
)
3.25
"Troglitazone (Tro) is a thiazolidinedione antidiabetic drug that was withdrawn from the market due to its association with idiosyncratic severe liver injury. "( Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury.
Kakuni, M; Katoh, Y; Matsuo, K; Morita, M; Nakajima, M; Tateno, C; Yokoi, T, 2012
)
2.06
"Troglitazone (TGZ) is an antidiabetic agent of the thiazolidinedione (TZD) class that potentiates insulin action. "( Troglitazone improves blood flow by inhibiting neointimal formation after balloon injury in Otsuka Long-Evans Tokushima fatty rats.
Cho, KY; Kim, DK; Lee, MK; Min, KM; Park, GS; Park, SW; Song, MS, 2002
)
3.2
"Troglitazone is an oral antidiabetic drug that is a ligand for peroxisome proliferator activated receptor gamma (PPARgamma). "( Pretreatment with troglitazone decreases lethality during endotoxemia in mice.
Gimble, J; Gipson, J; Gonzalez, F; Hill, M; Hoffhines, A; Johnson, J; Novosad, B; Peters, J; Reynolds, K, 2002
)
2.09
"Troglitazone (TGZ) is an orally active antihyperglycemic agent used in the treatment of noninsulin-dependent diabetes mellitus. "( Identification of glutathione conjugates of troglitazone in human hepatocytes.
Fackett, A; Li, AP; Lloyd, S; McClellan, HA; Prabhu, S; Silber, PM; Terrell, CM, 2002
)
2.02
"Troglitazone (TGZ) is a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand that has pro-apoptotic activity in human colon cancer. "( Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma ) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity.
Baek, SJ; Eling, TE; Hsi, LC; Wilson, LC, 2003
)
3.2
"Troglitazone is a 2,4-thiazolidinedione antidiabetic agent with insulin-sensitizing activities. "( A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus.
Furukawa, H; Haruyama, H; Izumi, T; Koga, T; Koishi, R; Matsushita, Y; Miyoshi, K; Nakamura, K; Shimizu, M; Sugawara, M; Takahashi, T; Tomita, A; Watanabe, I; Yasumo, H, 2003
)
2
"Troglitazone (TRG) is an antidiabetic agent that increases the insulin sensitivity of target tissues in non-insulin-dependent diabetes mellitus. "( Troglitazone reduces heat shock protein 70 content in primary rat hepatocytes by a ubiquitin proteasome independent mechanism.
Bharadwaj, LA; Davies, GF; Ovsenek, N; Roesler, WJ, 2003
)
3.2
"Troglitazone is a potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARgamma) that is a ligand-activated transcription factor regulating cell differentiation and growth. "( Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines.
Clark, OH; Cotter, P; Duh, QY; Ginzinger, DG; Hyun, WC; Kanauchi, H; Lobo, M; Park, JW; Wong, MG; Zarnegar, R, 2005
)
3.21
"Troglitazone (TRG) is an anti-diabetic thiazolidinedione drug previously used to treat insulin-resistance in Type 2 diabetes."( Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells.
Davies, GF; Harkness, TA; Juurlink, BH; Roesler, WJ, 2005
)
2.49
"Troglitazone is a thiazolidinedione antidiabetic agent with insulin-sensitizing activities that was withdrawn from the market in 2000 due to its association with idiosyncratic hepatotoxicity. "( Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction.
Kaneko, S; Katoh, K; Maniratanachote, R; Nakajima, M; Sawazaki, T; Shibata, A; Tokudome, S; Wakasugi, T; Yamamori, I; Yokoi, T, 2005
)
2.01
"Troglitazone (T) is a member of a new class of antidiabetic drugs termed thiazolidinediones (TZDs), which has previously been used as an anti-diabetic agent. "( Troglitazone inhibits long-term glycation and oxidation of low-density lipoprotein.
Menzel, EJ; Sinzinger, H; Sobal, G, 2005
)
3.21
"Troglitazone is a member of the class of thiazolidinediones that are known to act as insulin-sensitizing agents. "( Effect of troglitazone on tumor necrosis factor alpha and transforming growth factor beta expression and action in human adipocyte precursor cells in primary culture.
Birgel, M; Hauner, H; Lee, YM; Skurk, T, 2006
)
2.18
"Troglitazone is an inductor of PPARgamma in colon cancer cells and inhibits PPARgamma-dependently proliferation, which may attribute to cell cycle G1 arrest and apoptosis in colon cancer cells. "( Effect of ligand troglitazone on peroxisome proliferator-activated receptor gamma expression and cellular growth in human colon cancer cells.
Luo, HS; Meng, XZ; Ming, M; Yu, HG; Yu, JP; Zhou, YH, 2006
)
2.12
"Troglitazone (TGZ) is a potential anticancer agent. "( Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line.
Chen, SL; Ho, TC; Lai, HY; Tsao, YP; Wu, JY; Yang, YC, 2007
)
2.07
"Troglitazone is a new orally active hypoglycemic agent that has been shown to ameliorate insulin resistance and hyperinsulinemia in both diabetic animal models and non-insulin-dependent diabetes mellitus (NIDDM) subjects. "( Metabolic effects of troglitazone on fat-induced insulin resistance in the rat.
Gao, KM; Khoursheed, M; Lee, MK; Miles, PD; Moossa, AR; Olefsky, JM, 1995
)
2.05
"Troglitazone is a newly developed antidiabetic agent that shows hypoglycemic effects in insulin-resistant animal models and non-insulin-dependent diabetic humans. "( Acute effects of troglitazone on in vivo insulin action in normal rats.
Lee, MK; Olefsky, JM, 1995
)
2.07
"Troglitazone (CS-045) is a newly developed antidiabetic agent that enhances insulin sensitivity."( Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.
Ikegami, H; Masuo, K; Mikami, H; Ogihara, T; Rakugi, H, 1995
)
1.28
"Troglitazone is a new orally active hypoglycemic agent that has been shown to reduce insulin resistance and hyperinsulinemia in both diabetic animal models and non-insulin-dependent diabetes mellitus (NIDDM) subjects. "( Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat.
Gao, KM; Khoursheed, M; Lee, MK; Miles, PD; Moossa, AR; Olefsky, JM, 1994
)
2.05
"Troglitazone (CS-045) is a new oral antidiabetic drug reported to be effective in insulin-resistant diabetes and to show antihypertensive effects. "( Photooxidation of troglitazone, a new antidiabetic drug.
Foote, CS; Fu, Y; Fujita, T; Sheu, C, 1996
)
2.07
"Troglitazone is a new antidiabetic agent that exhibits a high-metabolic clearance and is metabolized mainly in the liver to sulfate and glucuronide conjugates."( Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach.
Enomoto, S; Hosiyama, K; Izumi, T; Nakagawa, T; Sasahara, K; Shibukawa, A; Sugiyama, Y, 1996
)
1.28
"Troglitazone is an insulin-sensitizing thiazolidinedione, which improves hepatic and skeletal muscle insulin resistance in NIDDM and obesity."( Effect of troglitazone on leptin production. Studies in vitro and in human subjects.
Caro, JF; Considine, RV; Nolan, JJ; Nyce, MR; Olefsky, JM, 1996
)
1.42
"Troglitazone is a member of the thiazolidinedione class of compounds, which act as insulin-sensitizing agents when administered to human patients and animal models displaying noninsulin-dependent diabetes mellitus. "( Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes.
Tafuri, SR, 1996
)
3.18
"Troglitazone (TRG) is an orally active antidiabetic agent that increases insulin sensitivity in models of non-insulin-dependent diabetes mellitus (NIDDM), subsequently reducing hyperinsulinemia and hyperglycemia. "( Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus.
Cornicelli, JA; Davis, JA; O'Rourke, CM; Saltiel, AR, 1997
)
2.06
"Troglitazone is a thiazolidinedione under development for the treatment of NIDDM and potentially other insulin-resistant disease states. "( Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.
Antonucci, TK; Driscoll, JH; Faja, BW; Ghazzi, MN; Huang, SM; Perez, JE; Whitcomb, RW, 1997
)
2.02
"Troglitazone is a newly developed antidiabetic drug that has been shown to improve insulin resistance and hyperinsulinemia both in diabetic animal models and in patients with non-insulin-dependent diabetes mellitus. "( Quantification of the effects of troglitazone on insulin sensitivity and beta-cell function in Watanabe heritable hyperlipidemic rabbits: a minimal model analysis.
Arakawa, K; Saku, K; Zhang, B, 1997
)
2.02
"Troglitazone (CS-045) is a new type of antidiabetic agent that decreases plasma glucose by enhancing insulin action in insulin-resistant diabetic animals and non-insulin-dependent diabetes mellitus (NIDDM) patients. "( Acute effect of troglitazone on glucose metabolism in the absence or presence of insulin in perfused rat hindlimb.
Fujiwara, T; Horikoshi, H; Ikeda, K; Okuno, A; Shiota, M; Sugano, T; Yoshioka, S, 1997
)
2.09
"Troglitazone is a novel oral antidiabetic drug which has similarities in structure with vitamin E."( Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers.
Campagnola, M; Capriati, A; Cominacini, L; Contessi, GB; Davoli, A; Fratta Pasini, A; Garbin, U; Lo Cascio, V; Rigoni, A; Young, MM, 1997
)
2.46
"Troglitazone is a new orally active hypoglycemic agent that has been shown to ameliorate insulin resistance and hyperinsulinemia in both diabetic animal models and NIDDM subjects."( TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone.
Cohen, A; Higo, K; Miles, PD; Olefsky, JM; Rafaat, K; Romeo, OM, 1997
)
1.25
"Troglitazone is a new oral antidiabetic agent and has been reported to reduce insulin resistance and improve peripheral hyperinsulinemia in patients with noninsulin-dependent diabetes mellitus. "( Effect of troglitazone on blood insulin levels after pancreas transplantation with systemic venous drainage in rats.
Mitsuo, M; Nakai, I; Oka, T; Shimizu, Y; Uchiyama, K; Yasunami, Y, 1997
)
2.14
"Troglitazone is a new insulin-sensitizing agent used to treat type 2 diabetes mellitus. "( Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Buchanan, TA; Burant, CF; Cline, G; Gumbiner, B; Hsueh, WA; Inzucchi, S; Kelley, D; Maggs, DG; Nolan, J; Olefsky, JM; Polonsky, KS; Shulman, GI; Silver, D; Valiquett, TR, 1998
)
2.06
"Troglitazone is an orally active anti-diabetic agent. "( Concomitant administration of cholestyramine influences the absorption of troglitazone.
Eastmond, R; Lettis, S; Young, MA, 1998
)
1.97
"Troglitazone is a new oral antidiabetic drug that increases the sensitivity of peripheral tissues to insulin. "( Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
Fonseca, V; Graveline, JF; Raskin, P; Schwartz, S, 1998
)
2.15
"Troglitazone is an orally active hypoglycemic agent that has been shown to ameliorate insulin resistance and hyperinsulinemia in both diabetic animal models and NIDDM subjects."( Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance.
Higo, K; Lee, MK; Miles, PD; Olefsky, JM; Rafaat, K; Romeo, OM, 1998
)
2.46
"Troglitazone appears to be a safe, effective, and useful new agent in the treatment of insulin-requiring type 2 diabetes mellitus patients, although its HbA1C-lowering effects have been minimal in short-term trials, and its insulin dosage-reduction activity remains unclear. "( Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
Campbell, LK; Campbell, RK; Johnson, MD, 1998
)
3.19
"Troglitazone acts as an insulin sensitizer."( Troglitazone: an antidiabetic agent.
Chen, C, 1998
)
2.46
"Troglitazone (Rezulin) is a promising new oral hypoglycemic agent recently approved by the Federal Drug Administration for use in type II diabetes mellitus. "( Potential interaction of troglitazone and cyclosporine.
Bonomini, L; DeFranco, P; Friedman, G; Jacobs, M; Kaplan, B; Lyman, N; Mulgaonkar, SP; Viscuso, R, 1998
)
2.05
"Troglitazone is a new drug for the treatment of type 2 diabetes. "( Troglitazone-induced hepatic failure leading to liver transplantation. A case report.
Brunt, EM; Isley, WL; Neuschwander-Tetri, BA; Oki, JC; Phillips, NJ; Quiason, SG; Ramrakhiani, S, 1998
)
3.19
"Troglitazone is a novel once-daily oral antidiabetic agent for the treatment of type 2 diabetes patients. "( Establishing the dose response curve for metabolic control with troglitazone, an insulin action enhancer, in type 2 diabetes patients.
Eastmond, R; Eckland, DJ; Lettis, S; Young, MA, 1998
)
1.98
"Troglitazone is an agonist of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), which has been shown to improve the metabolic control of type 2 diabetes. "( Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency.
Ott, P; Ranek, L; Young, MA, 1998
)
2.07
"Troglitazone is a new class of antidiabetic agent possessing radical scavenging ability similar to vitamin E. "( Troglitazone, a new antidiabetic agent possessing radical scavenging ability, improved decreased skin blood flow in diabetic rats.
Fujiwara, T; Horikoshi, H; Ikeda, K; Matsuda, K; Ohsawa, T; Okuno, A; Takahashi, S; Ushiyama, S, 1998
)
3.19
"Troglitazone is an oral hypoglycemic agent that enhances the action of insulin."( Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes.
Avena, R; Curry, KM; Mitchell, ME; Nylen, ES; Sidawy, AN, 1998
)
1.02
"Troglitazone is a new oral hypoglycemic agent that reduces insulin resistance in non-insulin-dependent diabetes mellitus (NIDDM). "( Relationships between apolipoprotein(a) phenotype and increase of lipoprotein(a) by troglitazone.
Matsumoto, K; Miyake, S; Tominaga, Y; Ueki, Y; Yano, M, 1999
)
1.97
"Troglitazone is a new antidiabetic drug with a combined chemical structure of thiazolidinedione and alpha-tocopherol like structure (chroman ring). "( Inhibition of galactose-induced cataractogenesis by troglitazone, a new antidiabetic drug with an antioxidant property, in rat lens culture.
Horikoshi, H; Inoue, T; Yokoyama, T; Yoshida, Y, 1999
)
2
"Troglitazone is a thiazolidinedione used for the treatment of NIDDM and potentially for other insulin-resistant disease states. "( Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts.
Hisatome, I; Ikeda, T; Ogino, K; Shimoyama, M; Tanaka, Y, 1999
)
2
"Troglitazone is a new oral insulin-sensitizing agent from the thiazolidinedione group of compounds that has been developed in Japan Thiazolidinediones improve the insulin sensitivity at muscle, adipose tissue and liver. "( [Insulin-sensitizing agent].
Yamanouchi, T, 1999
)
1.75
"Troglitazone is an antidiabetic agent of the thiazolidinedione family. "( Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma.
Leff, T; Su, TZ; Wang, M; Wise, SC, 1999
)
3.19
"Troglitazone is a new anti-diabetic agent for the treatment of type 2 diabetes. "( Troglitazone has no effect on red cell mass or other erythropoietic parameters.
Dogterom, P; Jonkman, JH; Squassante, L; van Marle, SP; Wemer, J; Young, MM, 1999
)
3.19
"Troglitazone is a valuable addition to the arsenal of antidiabetic drugs for type 2 diabetes."( Troglitazone. Is it all over?
Hoekstra, JB; Kuck, EM; Wagenaar, LJ, 1999
)
2.47
"Troglitazone is an oral insulin-sensitizing drug used to treat patients with type 2 diabetes. "( Troglitazone inhibits expression of the phosphoenolpyruvate carboxykinase gene by an insulin-independent mechanism.
Davies, GF; Khandelwal, RL; Roesler, WJ, 1999
)
3.19
"Troglitazone is a new, orally effective antidiabetic agent that decreases plasma glucose in obese patients with non-insulin-dependent diabetes mellitus. "( Troglitazone inhibits bicarbonate secretion in rat and human duodenum.
Fukuda, K; Hosokawa, M; Kodama, M; Nakamura, H; Onomura, M; Oya, M; Seino, Y; Tsukada, H; Yamada, Y, 1999
)
3.19
"Troglitazone is a new thiazolidinedione oral antidiabetic agent approved for use to improve glycaemic control in patients with type 2 diabetes. "( Clinical pharmacokinetics of troglitazone.
Koup, JR; Loi, CM; Randinitis, E; Vassos, A; Young, M, 1999
)
2.04
"Troglitazone (TRO) is an insulin sensitizer used in the treatment of type II diabetes. "( Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes.
Dorko, K; Esplen, JE; Komoroski, BJ; Kostrubsky, VE; Ramachandran, V; Strom, SC; Venkataramanan, R; Zhang, S, 1999
)
3.19
"Troglitazone is a useful new oral antihyperglycemic agent, but in about 1.9% of patients hepatotoxicity has occurred, which may be severe and even fatal."( Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.
Banner, BF; Bonkovsky, HL; Kohlroser, J; Mathai, J; Reichheld, J, 2000
)
1.34
"Troglitazone is an insulin sensitizer which affects a number of target tissues. "( Troglitazone induces expression of PPARgamma in liver.
Davies, GF; Khandelwal, RL; Roesler, WJ,
)
3.02
"Troglitazone is a nuclear peroxisome proliferator-activated receptor-gamma agonist with insulin-sensitizing properties that has been introduced for the treatment of type 2 diabetes. "( Troglitazone directly inhibits CO(2) production from glucose and palmitate in isolated rat skeletal muscle.
Brunmair, B; Fürnsinn, C; Neschen, S; Roden, M; Waldhäusl, W, 2000
)
3.19
"Troglitazone (TRO) is an oral insulin-sensitizer that has direct effects on the vasculature to inhibit cell growth and migration. "( Troglitazone inhibits mitogenic signaling by insulin in vascular smooth muscle cells.
Fleck, E; Goetze, S; Graf, K; Hsueh, WA; Kim, S; Law, RE; Meehan, WP; Xi, XP; Yang, DC, 2000
)
3.19
"Troglitazone acts as a partial agonist for PPAR-gamma in transfected muscle (C2C12) and kidney (HEK 293T) cells, producing a submaximal transcriptional response (1.8- to 2.5-fold activation) compared with rosiglitazone (7.4- to 13-fold activation)."( Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.
Camp, HS; Frankowski, CL; Hong, YH; Leff, T; Li, O; Shen, X; Vanbogelen, R; Wise, SC, 2000
)
1.26
"Troglitazone is a CYP3A4 isoenzyme inducer known to decrease the plasma concentration of drugs metabolized by CYP3A4. "( Potential interaction between troglitazone and atorvastatin.
DiTusa, L; Luzier, AB, 2000
)
2.04
"Troglitazone is an insulin-sensitizing agent used to treat type 2 diabetes mellitus. "( Troglitazone-induced fulminant hepatitis: report of a case with autopsy findings.
Heller, DS; Klein, KM; Leevy, CB; Li, H; Zierer, KG,
)
3.02
"Troglitazone is a novel insulin-sensitizing agent that improves hyperglycemia and hyperinsulinemia in insulin-resistant diabetes mellitus."( Effect of troglitazone on exocrine pancreas in rats with streptozotocin-induced diabetes mellitus.
Fujiwara, T; Hayashi, N; Horikoshi, H; Shimizu, K; Shiratori, K, 2000
)
1.43
"Troglitazone is a newly developed antidiabetic drug and is indicated to be useful for the treatment of patients with type II diabetes mellitus. "( Troglitazone prevents fatty changes of the liver in obese diabetic rats.
Abe, S; Akiyama, T; Jia, DM; Otsuki, M; Tabaru, A, 2000
)
3.19
"Troglitazone is an antidiabetic agent that improves the ability of adipocytes to store triglycerides by enhancing their insulin sensitivity. "( Paradoxical effect of troglitazone in normal animals: enhancement of adipocyte but reduction of liver insulin sensitivity.
Ader, M; Bergman, RN; Dea, MK; Mittelman, SD; Sunehag, AL; Van Citters, GW, 2000
)
2.06
"Troglitazone is a thiazolidinedione insulin sensitizer drug for the treatment of type 2 non-insulin-dependent diabetes mellitus (NIDDM). "( Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat.
Funk, C; Pantze, M; Ponelle, C; Scheuermann, G, 2001
)
2.06
"Troglitazone is a thiazolidinedione and peroxisome proliferator-activated receptor gamma (PPARgamma) ligand used to treat diabetes mellitus type II. "( A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.
Battle, EH; Caldwell, SH; Hespenheide, EE; Iezzoni, JC; Redick, JA; Sheppard, BL, 2001
)
2.02
"Troglitazone is a potent inhibitor of progesterone release from porcine granulosa cells. "( Troglitazone is a competitive inhibitor of 3beta-hydroxysteroid dehydrogenase enzyme in the ovary.
Gasic, S; Green, A; Nagamani, M; Urban, RJ, 2001
)
3.2
"Troglitazone is a useful new thiazolidinedione oral antidiabetic agent, but it is unpredictably hepatotoxic in about 1.9% of patients. "( Inhibitory effect of troglitazone on glucuronidation catalyzed by human uridine diphosphate-glucuronosyltransferase 1A6.
Bamba, T; Fujiyama, Y; Ito, M; Sato, H; Yamamoto, K, 2001
)
2.07
"Troglitazone is a thiazolidinedione with insulin-sensitizing activities when administered to humans or animals with type 2 diabetes mellitus. "( Case of the month. Hepatic and renal failure in a patient taking troglitazone and metformin.
Chaudhry, MU; Simmons, DL, 2001
)
1.99
"Troglitazone is a potent stimulator of adipogenesis acting at the nuclear receptor: peroxisome proliferator activated receptor-gamma (PPARgamma)."( Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice.
Falk, E; Justesen, J; Kassem, M; Mosekilde, LI; Tornvig, L, 2001
)
2.47
"Troglitazone is a peroxisome proliferator-activated receptor-gamma agonist that has been shown to halt mesangium expansion in experimental models of type 2 diabetes mellitus and to act directly on rat mesangial cells. "( Troglitazone inhibits glutamine metabolism in rat mesangial cells.
McCarthy, K; Routh, R; Welbourne, T, 2002
)
3.2
"Troglitazone is an antidiabetic agent that increases the insulin sensitivity of target tissues in non-insulin-dependent diabetes mellitus. "( Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells.
Nakajima, M; Yamamoto, Y; Yamazaki, H; Yokoi, T, 2001
)
2.02

Effects

Troglitazone has an alpha-tocopherol (vitamin E) moiety that is not present in other TZDs. Treatment of hepatocytes with vitamin E led to an inhibition of PEPCK gene expression.

Troglitazone (Lot T003) has two melting points, about 120 and 175 degrees C. It has potential cardiotoxicity at high doses but, at lower concentrations, does not prevent cardiac lipotoxicity, which can be completely prevented by low concentrations of oleic acid.

ExcerptReferenceRelevance
"Troglitazone has a mild adverse effect profile, with rare instances of abnormal liver function tests."( Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
Campbell, LK; Campbell, RK; Johnson, MD, 1998
)
2.46
"Troglitazone also has a lowering effect on the levels of triglycerides."( Troglitazone. Is it all over?
Hoekstra, JB; Kuck, EM; Wagenaar, LJ, 1999
)
2.47
"Troglitazone has an alpha-tocopherol (vitamin E) moiety that is not present in other TZDs, and treatment of hepatocytes with vitamin E led to an inhibition of PEPCK gene expression."( Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-gamma (PPARgamma)-independent, antioxidant-related mechanism.
Davies, GF; Juurlink, BH; Khandelwal, RL; Roesler, WJ; Wu, L, 2001
)
1.26
"Troglitazone has been used to suppress the growth of a number of tumors through apoptosis and autophagy. "( Cancer drug troglitazone stimulates the growth and response of renal cells to hypoxia inducible factors.
Taub, M, 2016
)
2.26
"Troglitazone has potential cardiotoxicity at high doses but, at lower concentrations, does not prevent cardiac lipotoxicity, which can be completely prevented by low concentrations of oleic acid."( Stearic acid-induced cardiac lipotoxicity is independent of cellular lipid and is mitigated by the fatty acids oleic and capric acid but not by the PPAR agonist troglitazone.
Lodha, P; Lodhia, P; Rabkin, SW, 2009
)
1.27
"Troglitazone has been shown to cause growth inhibition of various normal and cancerous cells."( Identification of troglitazone responsive genes: induction of RTP801 during troglitazone-induced apoptosis in Hep 3B cells.
Hong, SH; Kim, JC; Kim, JO; Kim, JY; Kim, MK; Kwack, MH; Sung, YK, 2010
)
1.42
"Troglitazone has been withdrawn from therapeutic options for diabetes mellitus because of its severe hepatocyte toxicity of unknown pathogenesis. "( Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes.
Hanada, S; Harada, M; Koga, H; Kumashiro, R; Kumemura, H; Namba, M; Ohira, H; Sata, M; Sato, Y; Shishido, S; Taniguchi, E; Ueno, T, 2003
)
2.01
"Troglitazone has been evaluated in numerous clinical trials of women with PCOS. "( Thiazolidinediones for treatment of polycystic ovary syndrome.
Fugate, SE; Stout, DL, 2005
)
1.77
"Troglitazone (Lot T003) has two melting points, about 120 and 175 degrees C."( Effects of water content in physical mixture and heating temperature on crystallinity of troglitazone-PVP K30 solid dispersions prepared by closed melting method.
Furuyama, N; Hamaura, T; Hasegawa, S; Kusai, A; Terada, K; Yonemochi, E, 2005
)
1.27
"Troglitazone has been shown to lower serum insulin levels and protect beta cell function."( Troglitazone acutely activates AMP-activated protein kinase and inhibits insulin secretion from beta cells.
Fu, X; Gu, Y; Li, F; Li, G; Li, J; Luo, M; Luo, T; Qian, L; Shao, L; Wang, X; Zheng, S; Zhou, L, 2007
)
2.5
"Troglitazone, which has previously been shown to activate AMPK, similarly inhibited MM cell growth, activated AMPK, and decreased ERK and P70S6K phosphorylation."( Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells.
Baumann, P; Emmerich, B; Mandl-Weber, S; Schmidmaier, R; Straka, C, 2007
)
1.06
"Troglitazone has a mild adverse effect profile, with rare instances of abnormal liver function tests."( Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
Campbell, LK; Campbell, RK; Johnson, MD, 1998
)
2.46
"Troglitazone has been shown to be efficacious in treating NIDDM, both as monotherapy and in combination with oral sulfonylureas."( Troglitazone: an antidiabetic agent.
Chen, C, 1998
)
2.46
"Troglitazone also has potential disadvantages."( Troglitazone in type II diabetes mellitus.
Seaton, TL; Sparano, N,
)
2.3
"Troglitazone has recently been introduced in the treatment of Type 2 diabetes. "( Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse.
Batchelor, K; Beales, PE; Giorgini, AE; Liddi, R; Pozzilli, P; Procaccini, E; Signore, A, 1998
)
3.19
"Troglitazone has recently been shown to increase cardiac output and stroke volume in human subjects."( Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts.
Hisatome, I; Ikeda, T; Ogino, K; Shimoyama, M; Tanaka, Y, 1999
)
1.28
"Troglitazone also has a lowering effect on the levels of triglycerides."( Troglitazone. Is it all over?
Hoekstra, JB; Kuck, EM; Wagenaar, LJ, 1999
)
2.47
"Troglitazone has been shown to exert additional beneficial effects on serum lipid profile and arterial blood pressure."( Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
Lefèbvre, PJ; Scheen, AJ, 1999
)
2.47
"Troglitazone (600 mg/day) has greater insulin-sparing effects than metformin (1,700 mg/day) in CSII-treated euglycemic patients."( A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Kruszynska, YT; Mulford, MI; Olefsky, JM; Yu, JG, 1999
)
1.37
"Troglitazone has low and variable oral bioavailability."( Pharmacokinetics of the insulin-sensitizing agent troglitazone in cats.
Boudinot, FD; Ferguson, DC; Hoenig, M; Michels, GM, 2000
)
1.28
"Troglitazone has direct effects on the hemodynamics of the heart. "( Acute hemodynamic effects of insulin-sensitizing agents in isolated perfused rat hearts.
Hisatome, I; Ogino, K; Shigemasa, C; Shimoyama, M; Uchida, K, 2000
)
1.75
"Troglitazone has been shown to improve insulin sensitivity and thereby exert hypoglycemic effects in various animal models and humans with insulin resistance and diabetes. "( Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
Akiyama, T; Fukumitsu, KI; Jia, DM; Nakamura, H; Otsuki, M; Tabaru, A, 2000
)
3.19
"Troglitazone has been reported to be beneficial in a small group of patients with nonalcoholic steatohepatitis (NASH)."( Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus.
Angulo, P; Lindor, KD, 2001
)
1.31
"Troglitazone has an alpha-tocopherol (vitamin E) moiety that is not present in other TZDs, and treatment of hepatocytes with vitamin E led to an inhibition of PEPCK gene expression."( Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-gamma (PPARgamma)-independent, antioxidant-related mechanism.
Davies, GF; Juurlink, BH; Khandelwal, RL; Roesler, WJ; Wu, L, 2001
)
1.26
"Troglitazone, which has no effect on PDE3B in liver, increased the expression of this gene in adipocytes."( Phosphodiesterase 3B gene expression is enhanced in the liver but reduced in the adipose tissue of obese insulin resistant db/db mouse.
Makino, H; Nishimiya, T; Ochi, M; Onuma, H; Osawa, H; Sugita, A; Tang, Y, 2001
)
1.03
"Troglitazone has been shown to improve peripheral insulin resistance in type 2 diabetic patients and animal models. "( Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus.
Adachi, Y; Araki-Sasaki, R; Furuta, M; Gabazza, EC; Hori, Y; Katsuki, A; Nakatani, K; Sumida, Y; Tanaka, T; Yano, Y, 2002
)
3.2

Actions

Troglitazone and 15dPGJ2 inhibit growth of prostate and bladder carcinoma cell lines through different mechanisms. Both agents are PPARgamma-independent. It does not cause hepatotoxicity in normal healthy rodents, but it produces mitochondrial injury in vitro.

ExcerptReferenceRelevance
"Troglitazone was found to increase mitochondrial permeability transition (MPT) in the liver mitochondria of diabetic rats to a greater extent than in control rats, whereas mitochondrial membrane potential and oxidative phosphorylation were not affected."( Increased susceptibility to troglitazone-induced mitochondrial permeability transition in type 2 diabetes mellitus model rat.
Ito, K; Sato, T; Segawa, M; Sekine, S, 2018
)
1.5
"Troglitazone was found to inhibit the growth of HT29 cells by induction of apoptosis. "( Troglitazone induced apoptosis via PPARγ activated POX-induced ROS formation in HT29 cells.
DU, Y; Hu, X; Lv, X; Shi, J; Wang, J, 2011
)
3.25
"Troglitazone and 15d-PGJ2 inhibit them at the IkappaB protein level."( Troglitazone and 15-deoxy-delta(12,14)-prostaglandin J2 inhibit shear-induced coupling factor 6 release in endothelial cells.
Maeda, N; Magota, K; Murakami, R; Okumura, K; Osanai, T; Sasaki, S; Toki, T; Tomita, H; Yasujima, M, 2005
)
2.49
"Troglitazone and 15dPGJ2 inhibit growth of prostate and bladder carcinoma cell lines through different mechanisms and the effects of both agents are PPARgamma-independent."( PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma.
Chaffer, CL; Thomas, DM; Thompson, EW; Williams, ED, 2006
)
1.78
"Troglitazone does not cause hepatotoxicity in normal healthy rodents, but it produces mitochondrial injury in vitro at high concentrations."( Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities.
Boelsterli, UA; Latchoumycandane, C; Ong, MM, 2007
)
2.5
"Troglitazone did increase lactate and pyruvate release at concentrations of 20 mumol/L and higher; however, it decreased the ratio of lactate to pyruvate (L/P ratio) and increased oxygen consumption at concentrations higher than 5 and 20 mumol/L, respectively."( Acute effect of troglitazone on glucose metabolism in the absence or presence of insulin in perfused rat hindlimb.
Fujiwara, T; Horikoshi, H; Ikeda, K; Okuno, A; Shiota, M; Sugano, T; Yoshioka, S, 1997
)
1.36
"Troglitazone may cause subfulminant liver failure."( Troglitazone-induced hepatic failure leading to liver transplantation. A case report.
Brunt, EM; Isley, WL; Neuschwander-Tetri, BA; Oki, JC; Phillips, NJ; Quiason, SG; Ramrakhiani, S, 1998
)
3.19
"Thus troglitazone appears to enhance IL-1-induced NOS mRNA levels by prolonging its half-life rather than activating its transcription, which is nuclear factor -kappaB-dependent."( Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells.
Hattori, S; Hattori, Y; Kasai, K, 1999
)
2.2
"Troglitazone appears to increase both glycogen and TG turnover in skeletal muscle."( Effects of troglitazone on substrate storage and utilization in insulin-resistant rats.
Burant, CF; Cockburn, B; Fuller, T; Keck, S; Sreenan, S, 1999
)
1.41
"Troglitazone may enhance the activities of cytochrome P450 (CYP) 3A and/or transporter(s) thereby reducing the plasma concentrations of terfenadine, cyclosporin, atorvastatin and fexofenadine."( Clinical pharmacokinetics of troglitazone.
Koup, JR; Loi, CM; Randinitis, E; Vassos, A; Young, M, 1999
)
1.32
"Troglitazone and metformin lower glucose levels in diabetic patients without increasing plasma insulin levels. "( A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Kruszynska, YT; Mulford, MI; Olefsky, JM; Yu, JG, 1999
)
2.09
"Troglitazone promotes adipocyte differentiation in vitro and increases insulin sensitivity in vivo. "( Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.
Arioglu, E; Duncan-Morin, J; Gottlieb, N; Herion, D; Hoofnagle, J; Kleiner, DE; Lieberman, J; Premkumar, A; Reitman, ML; Reynolds, J; Rother, KI; Sebring, N; Sumner, AE; Taylor, SI, 2000
)
2.06
"This troglitazone-induced increase in the expression of aP2 and FAT/CD36 was markedly enhanced in the liver in ob/ob mice."( Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the li
Beigneux, A; Feingold, KR; Grunfeld, C; Memon, RA; Moser, AH; Nonogaki, K; Tecott, LH, 2000
)
0.96
"Troglitazone did not activate NF-kappaB, suggesting a role of NF-kappaB-independent pathways."( Ligands of peroxisome proliferator-activated receptor-gamma induce apoptosis in AR42J cells.
Masamune, A; Sakai, Y; Satoh, A; Satoh, K; Shimosegawa, T; Yoshida, M, 2002
)
1.04

Treatment

Troglitazone treatment decreased PI3K and pAkt expression in HG. Treatment increased gene expression of pro-inflammatory mediators and stress-related genes.

ExcerptReferenceRelevance
"Troglitazone treatment decreased PI3K and pAkt expression in HG."( The effect of PPARγ agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia.
Jung, HS; Kim, M; Kim, TK; Kim, TN; Kwon, MJ; Lee, EJ; Lee, SH; Park, JH; Rhee, BD; Shin, HM, 2017
)
1.18
"Troglitazone treatment results in decrease in α5 subunit expression on the cell surface."( 9-cis-retinoic Acid and troglitazone impacts cellular adhesion, proliferation, and integrin expression in K562 cells.
Gambill, J; Hanson, AM; Kelley, MD; Phomakay, V; Staten, CT, 2014
)
1.43
"Troglitazone-treated cells showed severe reductions of the oxygen consumption rate, indicating suppression of mitochondrial respiration, which was accompanied by significantly decreased mitochondrial membrane potential and increased concentration of reactive oxygen species."( Troglitazone Stimulates Cancer Cell Uptake of 18F-FDG by Suppressing Mitochondrial Respiration and Augments Sensitivity to Glucose Restriction.
Cho, YS; Jung, KH; Lee, JH; Lee, KH; Lee, SJ; Moon, SH; Park, JW; Quach, CH, 2016
)
2.6
"Troglitazone treatment of these cells also resulted in a dose-dependent increase in IL-1beta induced IkappaBalpha phosphorylation."( Troglitazone increases IL-1beta induced cyclooxygenase-2 and inducible nitric oxide synthase expression via enhanced phosphorylation of IkappaBalpha in vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats.
Choi, HC; Kang, YJ; Kim, HS, 2008
)
2.51
"Troglitazone treatment increased gene expression of pro-inflammatory mediators and stress-related genes in both cell types, which in general was more pronounced in co-cultures than in single cell cultures."( Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model.
Butura, A; Edling, Y; Ek, M; Ingelman-Sundberg, M; Sivertsson, LK, 2009
)
1.37
"Troglitazone treatment had no significant effect on LPS-induced plasma TNF, glucose, or nitric oxide levels in WT or PPARalpha null mice at any of the time points examined."( Pretreatment with troglitazone decreases lethality during endotoxemia in mice.
Gimble, J; Gipson, J; Gonzalez, F; Hill, M; Hoffhines, A; Johnson, J; Novosad, B; Peters, J; Reynolds, K, 2002
)
1.37
"Troglitazone treatment restored those alterations in PTPase activity in the particulate fraction and the amounts of LAR, PTP1B and SH-PTP2 in both fractions of visceral and epididymal adipose tissues of OLETF rats."( Troglitazone ameliorates abnormal activity of protein tyrosine phosphatase in adipose tissues of Otsuka Long-Evans Tokushima Fatty rats.
Homma, H; Honda, T; Ide, H; Kawakami, Y; Ohno, K; Sakaue, S; Tagami, S; Yoshimura, H, 2002
)
2.48
"Troglitazone treatment, which reduces nonadipose tissue TG of fa/fa rats without downregulating lipogenic enzymes, raised SCD-2 13-fold but lowered SCD-1 by 25%."( Effects of leptin, troglitazone, and dietary fat on stearoyl CoA desaturase.
Kakuma, T; Lee, Y; Unger, RH, 2002
)
1.36
"The troglitazone-treated cells showed a significant decline in the DeltaPsi(m) per unit mitochondrial volume but resulted in no clear cell death."( Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes.
Hanada, S; Harada, M; Koga, H; Kumashiro, R; Kumemura, H; Namba, M; Ohira, H; Sata, M; Sato, Y; Shishido, S; Taniguchi, E; Ueno, T, 2003
)
1.05
"Troglitazone treatment increased serum adiponectin levels nearly threefold."( Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.
Aroda, V; Bandukwala, R; Baxi, S; Carter, L; Ciaraldi, TP; Henry, RR; Kong, AP; Mudaliar, SR; Phillips, SA, 2003
)
1.04
"Troglitazone treatment of type 2 diabetic patients diminishes sCD40L levels, suggesting a novel antiinflammatory mechanism for limiting diabetes-associated arterial disease."( Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.
Bernal, MR; Calle-Pascual, AL; Fernández-Cruz, A; Goldfine, A; Horton, E; Jarolim, P; Libby, P; Nuzzo, R; Schönbeck, U; Varo, JJ; Varo, N; Veves, A; Vicent, D, 2003
)
1.04
"Troglitazone treatment of MA-10 Leydig tumor cells resulted in cellular cholesteryl esters decreasing and cell free cholesterol increasing. "( Effects of troglitazone on intracellular cholesterol distribution and cholesterol-dependent cell functions in MA-10 Leydig tumor cells.
Freeman, DA; Romero, A, 2003
)
2.15
"Troglitazone (TGZ) treatment, beginning at 6 weeks of age, prevented the hyperglycemia, the hyperlipidemia, and the increase in 11beta-HSD-1."( Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone.
Agarwal, AK; Duplomb, L; Lee, Y; Park, BH; Takaishi, K; Unger, RH; Wang, MY, 2004
)
1.27
"Troglitazone treatment increased the large LDL particle at 4 and 8 weeks, a change that significantly (P<0.05) enlarged the LDL particle size (20.5 +/- 0.3 nm, 21.2 +/- 0.3 nm, and 21.3 +/- 0.2 nm at baseline, week 4, and week 8, respectively)."( Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with type 2 diabetes independent of diabetic control.
Bavirti, S; Ghanaat, F; Tayek, JA,
)
0.85
"Troglitazone treatment improved all markers for severity of pancreatitis."( Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice.
Bruno, MJ; Daalhuisen, J; de Boer, AM; de Vos, AF; Florquin, S; van der Poll, T; van Westerloo, DJ, 2005
)
1.36
"Troglitazone treatment did not affect the mRNA levels of either Akt1 or Akt2, suggesting that a transcriptional mechanism was not involved, but caused a dramatic reduction in the content of muscular ceramides (76%, P<0.001), lipid-derived second messengers known to increase Akt degradation."( Increased Akt protein expression is associated with decreased ceramide content in skeletal muscle of troglitazone-treated mice.
Alegret, M; Laguna, JC; Planavila, A; Rodríguez-Calvo, R; Sánchez, RM; Vázquez-Carrera, M, 2005
)
1.27
"Troglitazone treatment resulted in an average 75% increase in the adiponectin levels, but no changes were observed in the endothelium-dependent vasodilation, any other measurement of vascular reactivity, or any other markers of endothelial activation. "( Troglitazone-induced changes in adiponectin do not affect endothelial function in diabetes.
Buras, J; Horton, ES; Orlow, D; Reenstra, WR; Veves, A, 2005
)
3.21
"Troglitazone treatment of these cells also resulted in a sustained increase in phosphorylation of ERK."( Troglitazone induction of COX-2 expression is dependent on ERK activation in keratinocytes.
Fischer, SM; He, G; Sung, YM, 2006
)
2.5
"Troglitazone treatment was found to result in a marked reduction of TNF-alpha mRNA expression in human preadipocytes to 54% +/- 13% compared with untreated cultures."( Effect of troglitazone on tumor necrosis factor alpha and transforming growth factor beta expression and action in human adipocyte precursor cells in primary culture.
Birgel, M; Hauner, H; Lee, YM; Skurk, T, 2006
)
1.46
"Troglitazone treatment inhibited activation of extracellular signal-regulated protein kinase (ERK) and stimulated p38 activation."( Role of mitogen-activated protein kinase (MAPK) in troglitazone-induced osteoblastic cell death.
Jung, JY; Kim, HT; Kim, YK; Kwon, CH; Park, JY; Yoo, CI, 2007
)
1.31
"Troglitazone treatment improved ischemic tolerance by improving glucose metabolism in the myocardium of those rats."( Exacerbation of acidosis during ischemia and reperfusion arrhythmia in hearts from type 2 Diabetic Otsuka Long-Evans Tokushima Fatty rats.
Anzawa, R; Horikoshi, K; Mochizuki, S; Seki, S; Taniguchi, M, 2007
)
1.06
"Troglitazone treatment induced weight gain, which tended to be greater in Ala12 carriers (p = 0.08)."( The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program.
Altshuler, D; Delahanty, L; Florez, JC; Franks, PW; Hanson, RL; Jablonski, KA; Kahn, SE; Knowler, WC, 2007
)
1.06
"Troglitazone treatment did not affect any of these parameters."( Metabolic effects of troglitazone on fat-induced insulin resistance in the rat.
Gao, KM; Khoursheed, M; Lee, MK; Miles, PD; Moossa, AR; Olefsky, JM, 1995
)
1.33
"Troglitazone treatment completely restored the GDR (submaximal 158.2 +/- 5.6, maximal 305.3 +/- 6.1 mumol.kg-1.min-1) and submaximal HGP (9.4 +/- 2.8 mumol.kg-1.min-1) to control levels and also normalized the elevated plasma triglyceride concentration and systolic blood pressure levels in fructose-fed rats.(ABSTRACT TRUNCATED AT 250 WORDS)"( Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat.
Gao, KM; Khoursheed, M; Lee, MK; Miles, PD; Moossa, AR; Olefsky, JM, 1994
)
1.33
"Troglitazone treatment led to a significant increase in insulin sensitivity, and there was a positive correlation between the change in insulin sensitivity and the change in plasma leptin concentration in these subjects."( Effect of troglitazone on leptin production. Studies in vitro and in human subjects.
Caro, JF; Considine, RV; Nolan, JJ; Nyce, MR; Olefsky, JM, 1996
)
1.42
"Troglitazone treatment did not attenuate the insulinopenia and hyperglycemia of diabetic rats, but it partially improved the hypertriglyceridemia."( Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats.
Higa, S; Komiya, I; Nagamine, F; Shimabukuro, M; Shinzato, T; Takasu, N, 1996
)
1.31
"Troglitazone treatment increased basal glucose transport 1.5- to 2.0-fold, whereas insulin-stimulated uptake was unaffected."( Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes.
Tafuri, SR, 1996
)
2.46
"Troglitazone treatment completely prevented the TNF-alpha-induced decline in submaximal GDR (133 +/- 16 vs."( TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone.
Cohen, A; Higo, K; Miles, PD; Olefsky, JM; Rafaat, K; Romeo, OM, 1997
)
1.25
"Troglitazone treatment decreased skeletal muscle, but not hepatic triglyceride and increased hepatic and muscle glycogen content in wild-type mice."( Troglitazone action is independent of adipose tissue.
Burant, CF; Davidson, NO; Graves, RA; Hirano, K; Lohmiller, J; Lukens, J; Ross, S; Sreenan, S; Tai, TA, 1997
)
2.46
"Troglitazone treatment resulted in a decrease in fasting plasma glucose from 11.2 +/- 0.7 to 9.6 +/- 0.9 mmol/L (P = 0.02)."( Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus.
Kahn, SE; Porte, D; Prigeon, RL, 1998
)
1.42
"Troglitazone treatment largely prevented the hyperglycemia-induced decline in submaximal (116 +/- 7 micromol x kg(-1) x min[-1]) and maximal GDR (209 +/- 9 micromol x kg(-1) x min(-1); P < 0.05)."( Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance.
Higo, K; Lee, MK; Miles, PD; Olefsky, JM; Rafaat, K; Romeo, OM, 1998
)
2.46
"Troglitazone treatment improved insulin sensitivity. "( Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects.
Demacker, PN; Smits, P; Stalenhoef, AF; Tack, CJ, 1998
)
3.19
"Troglitazone treatment increased PPARgamma mRNA levels up to 3-fold in muscle cultures from type II diabetics (277 +/- 63 to 630 +/- 100 x 10(3) copies/microg total RNA, P = 0.003) and in nondiabetic control subjects (200 +/- 42 to 490 +/- 81, P = 0.003)."( Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma.
Abrams-Carter, L; Ciaraldi, TP; Henry, RR; Lindgren, K; Mudaliar, S; Nikoulina, SE; Park, KS; Tufari, SR; Veerkamp, JH; Vidal-Puig, A, 1998
)
2.46
"Troglitazone treatment caused a significant decrease in PPARgamma proteins and DNA binding activity."( PPARgamma activators down-regulate the expression of PPARgamma in 3T3-L1 adipocytes.
Camp, HS; Tafuri, SR; Whitton, AL, 1999
)
1.02
"Troglitazone treatment resulted in attenuation of both hyperinsulinemia and hyperandrogenism in an obese woman with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy."( Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome.
Elkind-Hirsch, KE; McWilliams, RB, 1999
)
1.99
"Troglitazone treatment with MLDSTZ injection prevented hyperglycemia (230 +/- 30 mg/dl) and, suppressed insulitis and TNF alpha production from intraperitoneal exudate cells."( Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice.
Fujiwara, T; Fukushige, J; Horikoshi, H; Hosokawa, T; Izumi, T; Kurakata, S; Ogawa, J; Takahashi, S, 1999
)
2.47
"Troglitazone treatment produced a significant rise in the metabolic clearance rate of glucose (MCR) during the 6-mU/kg BW/min insulin clamp study (19.5+/-3.9 vs 9.9+/-1.5 ml/kg BW/min, mean+/-SE, P<0.05) in obese rats, but not in lean rats."( Troglitazone improves insulin-stimulated glucose utilization associated with an increased muscle glycogen content in obese Zucker rats.
Kako, M; Li, L; Nakai, N; Ohsawa, I; Oshida, Y; Sato, J; Sato, Y; Shimomura, Y, 1999
)
2.47
"Troglitazone treatment normalized the histological features of psoriatic skin in organ culture and reduced the epidermal hyperplasia of psoriasis in the severe combined immunodeficient mouse and human skin transplant model of psoriasis (P<.05 compared with untreated controls)."( Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation.
Benson, SC; Chi, Y; Ellis, CN; Fisher, GJ; Kurtz, TW; Pershadsingh, HA; Varani, J; Zeigler, ME, 2000
)
2.47
"Troglitazone treatment resulted in a significant increase in insulin sensitivity, as reported previously."( Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes.
Azen, SP; Berkowitz, K; Buchanan, TA; Goico, J; Kjos, SL; Marroquin, A; Ochoa, C; Peters, RK; Xiang, AH, 2000
)
1.03
"Troglitazone treatment increased expression of two cyclin-dependent kinase inhibitors, p21(WAF1/CIP1) and p16(INK4), and reduced cyclin D1 expression, consistent with G1 arrest."( Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death.
Breyer, MD; Breyer, RM; Davis, L; Guan, YF; Zhang, YH, 1999
)
1.02
"Troglitazone pre-treatment blocked the LPS-induced expression of iNOS in adipose tissue and the increase in serum nitrite concentration."( Troglitazone inhibits the expression of inducible nitric oxide synthase in adipocytes in vitro and in vivo study in 3T3-L1 cells and Otsuka Long-Evans Tokushima Fatty rats.
Asayama, K; Dobashi, K; Hayashibe, H; Kodera, K; Nakane, T; Nakazawa, S, 2000
)
2.47
"Troglitazone treatment was associated with increased citrate sensitivity of ACC."( Troglitazone stimulates acetyl-CoA carboxylase activity through a post-translational mechanism.
Haas, MJ; Mooradian, AD; Thampy, GK, 2000
)
2.47
"Troglitazone treatment significantly improved the left ventricular diastolic dynamics of DM rats: deceleration time (msec) of early diastolic inflow decreased significantly (treated 52 +/- 3 vs untreated 64 +/- 5, p = 0.0002), and peak velocity of early transmitral inflow (cm/sec) increased significantly (treated 96 +/- 7 vs untreated 86 +/- 8, p = 0.0216)."( Improvement of left ventricular diastolic dynamics in prediabetic stage of a type II diabetic rat model after troglitazone treatment.
Matsuo, H; Mizushige, K; Murakami, K; Noma, T; Ohmori, K; Yao, L, 2001
)
1.24
"Troglitazone treatment reduced SGLT1 mRNA and protein expression levels by 50% in ZDF and ZLC rats, but had no effect on mucosal mass or the expression levels of GLUT2 mRNA and protein, GLUT5 mRNA, and PPAR-gamma mRNA."( Effects of type-2 diabetes and troglitazone on the expression patterns of small intestinal sugar transporters and PPAR-gamma in the Zucker diabetic fatty rat.
Burant, C; Corpe, C; Sreenan, S, 2001
)
1.32
"Troglitazone treatment significantly increased pancreatic wet weight and protein, DNA, and enzyme contents compared with those in the control rats."( Troglitazone stimulates pancreatic growth in congenitally CCK-A receptor-deficient OLETF rats.
Akiyama, T; Fukumitsu, KI; Jia, DM; Otsuki, M; Tabaru, A, 2001
)
2.47
"Troglitazone treatment decreased adipose tissue GPX activity and abolished overproduction of TNF-alpha in OLETF rats."( Effect of obesity and troglitazone on expression of two glutathione peroxidases: cellular and extracellular types in serum, kidney and adipose tissue.
Asayama, K; Dobashi, K; Hayashibe, H; Kodera, K; Nakane, T; Nakazawa, S; Uchida, N, 2001
)
1.35
"Troglitazone treatment lowered SBP but did not reduce body weight."( Comparison of the metabolic effects of metformin and troglitazone on fructose-induced insulin resistance in male Sprague-Dawley rats.
Chang, CT; Chen, CC; Chen, RH; Sheen, LY; Shih, HC; Wang, HJ; Wang, TY, 2001
)
1.28
"Troglitazone treatment did not improve high-fat induced insulin resistance."( Effects of troglitazone and voluntary running on insulin resistance induced high fat diet in the rat.
Han, YQ; Kitakoshi, K; Nakai, N; Oshida, Y; Sato, Y, 2001
)
1.42
"In troglitazone-treated mice, AV/TV was significantly higher than in control mice (4.7+/-2.1% vs."( Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice.
Falk, E; Justesen, J; Kassem, M; Mosekilde, LI; Tornvig, L, 2001
)
2.27
"In troglitazone-treated monolayers, all of the glutamine nitrogen taken up could be accounted for as ammonium nitrogen released into the medium."( Troglitazone inhibits glutamine metabolism in rat mesangial cells.
McCarthy, K; Routh, R; Welbourne, T, 2002
)
2.27
"Troglitazone-treated subjects displayed a tendency toward weight gain (5 +/- 2 kg, P < 0.05), increased adipocyte size, and increased serum leptin levels."( Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects.
Baxi, S; Caulfield, M; Chu, NV; Ciaraldi, TP; Henry, RR; Kim, DD; Kong, AP; Loviscach, M; Mudaliar, S; Plodkowski, R; Reitz, R, 2002
)
1.28
"Troglitazone treatment resulted in a 35 +/- 9% improvement in GDR (P < 0.01), which was greater than (P < 0.05) the 22 +/- 13% increase (P < 0.05) after metformin treatment."( Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.
Chu, N; Ciaraldi, TP; Henry, RR; Kahn, BB; Kim, D; Kim, YB; Kong, A; Mohideen, P; Mudaliar, S, 2002
)
2.48
"Troglitazone treatment had a slight depressor effect (decreasing the blood pressure from 133 +/- 5/72 +/- 3 to 127 +/- 4/68 +/- 1 mmHg; p < 0.05)."( Effect of troglitazone on endothelial function in type 2 diabetic patients.
Dohi, Y; Gotoa, T; Hakamata, M; Hayashi, K; Sato, K; Takase, H; Toriyama, T; Ueda, R, 2002
)
1.44
"Troglitazone treatment significantly increased pancreatic protein and DNA contents, but the protein per DNA ratio, an indicator of cellular size, remained at nearly the same concentrations at all ages."( Troglitazone stimulates pancreatic growth in normal rats.
Jia, DM; Otsuki, M, 2002
)
2.48
"Troglitazone treatment did not increase ARC NPY gene expression either after a 72 h fast and re-feeding for 2 weeks (Experiment 1) or immediately after a 72 h fast (Experiment 2)."( Troglitazone treatment of aging Brown Norway rats improves food intake and weight gain after fasting without increasing hypothalamic NPY gene expression.
Marck, BT; Matsumoto, AM; Wolden-Hanson, T, 2002
)
2.48
"Treatment with troglitazone microspheres increased cell viability and activated the β-catenin in ADSCs."( Encapsulation of troglitazone and AVE0991 by gelation microspheres promotes epithelial transformation of adipose-derived stem cells.
Bai, X; Han, F; Han, J; Hu, D; Liu, M; Tao, K; Yang, X; Zhang, D; Zhang, Y, 2020
)
1.24
"Pretreatment of troglitazone induced activation of PPARγ in a dose-dependent manner."( PPARγ activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy flux.
Lee, YJ; Moon, JH; Nazim, UM; Park, SY; Seol, JW, 2017
)
1.11
"Cotreatment with troglitazone and lovastatin altered the epithelial-to-mesenchymal-transition (EMT) -related marker gene expression of the cells; specifically, E-cadherin expression increased and vimentin expression decreased."( Combined treatment with troglitazone and lovastatin inhibited epidermal growth factor-induced migration through the downregulation of cysteine-rich protein 61 in human anaplastic thyroid cancer cells.
Chin, LH; Hsu, SP; Liang, YC; Zhong, WB, 2015
)
1.05
"Treatment of troglitazone and PDT induced the growth retardation and cell death of DLD-1 cells in a dose-dependent manner, respectively. "( Troglitazone Enhances the Apoptotic Response of DLD-1 Colon Cancer Cells to Photodynamic Therapy.
Choi, YH; Ko, SH; Lee, JM; Park, H; Park, JH, 2016
)
2.25
"Treatment of troglitazone and PDT induced the growth retardation and cell death of DLD-1 cells in a dose-dependent manner, respectively. "( Troglitazone Enhances the Apoptotic Response of DLD-1 Colon Cancer Cells to Photodynamic Therapy.
Choi, YH; Ko, SH; Lee, JM; Park, H; Park, JH, 2016
)
2.25
"Co-treatment of troglitazone with a GSK-3β inhibitor (AR-a014418) or GSK-3β siRNA significantly augmented the inhibitory effect of troglitazone on the NFκB activity and on prostate cancer cell growth inhibition and apoptotic cell death."( Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFκB via suppression of GSK-3β expression.
Ban, JO; Han, SB; Hong, JT; Kang, KW; Moon, DC; Oh, JH; Son, SM; Song, HS; Song, MJ; Won, D, 2011
)
2.15
"Treatment with troglitazone delayed or prevented the onset of type 2 diabetes in high-risk Hispanic women."( Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.
Azen, SP; Berkowitz, K; Buchanan, TA; Goico, J; Hodis, HN; Kjos, SL; Marroquin, A; Ochoa, C; Peters, RK; Tan, S; Xiang, AH, 2002
)
0.65
"Treatment with troglitazone was found to increase whole-body insulin sensitivity in sucrose- and chow-fed rats, but had no effect on skeletal muscle glucose transport activity measured in isolated muscles from both dietary groups."( Effect of troglitazone on vascular and glucose metabolic actions of insulin in high-sucrose-fed rats.
Bachelard, H; Nadeau, A; Pitre, M; Santuré, M, 2003
)
1.06
"Treatment with troglitazone (30 mg/kg/day) for 15 days reduced insulin values and reversed the increase in PDK-4 mRNA levels, suggesting improved insulin sensitivity."( Impaired expression of NADH dehydrogenase subunit 1 and PPARgamma coactivator-1 in skeletal muscle of ZDF rats: restoration by troglitazone.
Cabrero, A; Jové, M; Laguna, JC; Michalik, L; Planavila, A; Salla, J; Vázquez-Carrera, M; Wahli, W, 2004
)
0.87
"Pretreatment with troglitazone or 15d-PGJ2 inhibited the shear-induced release and gene expression of CF6, whereas fenofibric acid, a PPAR-alpha ligand, had no influence on them."( Troglitazone and 15-deoxy-delta(12,14)-prostaglandin J2 inhibit shear-induced coupling factor 6 release in endothelial cells.
Maeda, N; Magota, K; Murakami, R; Okumura, K; Osanai, T; Sasaki, S; Toki, T; Tomita, H; Yasujima, M, 2005
)
2.09
"Co-treatment with troglitazone and epirubicin further downregulated the expression level of Bcl-2 and inhibited cell migration simultaneously."( [Troglitazone sensitizes effect of epirubicin on breast cancer cells].
Lv, JH; Meng, ZX; Sun, JX; Sun, YJ, 2006
)
1.57
"Treatment with troglitazone after the induction of pancreatitis reduced serum amylase activity."( Anti-inflammatory effects of PPAR-gamma agonists directly correlate with PPAR-gamma expression during acute pancreatitis.
Emerson, LL; Etherington, BH; Firpo, MA; Glasgow, RE; Hart, BJ; Jackson, HH; Jackson, JD; Mulvihill, SJ; Rollins, MD; Sudarshan, S; Yang, DT,
)
0.47
"Treatment with troglitazone also disrupted TGF beta 1-activated SAPK/JNK signaling, leading to decreased Smad2/3 transactivation activity and alpha-smooth muscle actin expression."( Differentiation of human circulating fibrocytes as mediated by transforming growth factor-beta and peroxisome proliferator-activated receptor gamma.
Belperio, JA; Burdick, MD; Hong, KM; Keane, MP; Strieter, RM, 2007
)
0.68
"Treatment with troglitazone is associated with an improvement in hyperglycemia, hyperinsulinemia, and insulin-mediated glucose disposal."( Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.
Antonucci, TK; Driscoll, JH; Faja, BW; Ghazzi, MN; Huang, SM; Perez, JE; Whitcomb, RW, 1997
)
0.92
"Treatment with troglitazone alleviated the hyperglycemia, normalized the tolerance to intraperitoneally injected glucose, and significantly decreased elevated insulin levels."( Troglitazone action is independent of adipose tissue.
Burant, CF; Davidson, NO; Graves, RA; Hirano, K; Lohmiller, J; Lukens, J; Ross, S; Sreenan, S; Tai, TA, 1997
)
2.08
"Pretreatment with troglitazone and vitamin E, but not with pioglitazone, resulted in decreases in thrombin-induced phosphatidic acid production, hydrolysis of phosphatidylinositol 4,5-bisphosphate by phospholipase C, and 47-kDa protein phosphorylation."( Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism.
Ishizawa, M; Ishizuka, T; Itaya, S; Kajita, K; Kanoh, Y; Kimura, M; Miura, A; Muto, N; Wada, H; Yasuda, K, 1998
)
0.87
"Treatment with troglitazone for 2 wk resulted in increased heart and brown fat weights but in decreased white fat weight."( Troglitazone-induced heart and adipose tissue cell proliferation in mice.
Breider, MA; de la Iglesia, FA; Gough, AW; Haskins, JR; Sobocinski, G,
)
1.91
"Pretreatment with troglitazone or D-chiroinositol had no effect on fasting plasma glucose or insulin or basal hepatic glucose output (HGO)."( Differential effects of troglitazone and D-chiroinositol on glucosamine-induced insulin resistance in vivo in rats.
Hattori, J; Kawachi, S; Nakashima, K; Okumura, S; Sasaki, A; Sugimoto, M; Takami, K; Takami, R; Takeda, N; Yasuda, K; Yoshino, K, 1999
)
0.93
"Treatment with troglitazone 400 mg q.d."( Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus.
Brinkmann, L; Goebel, FD; Michl, GM; Mühlbayer, D; Walli, R, 2000
)
1.04
"Treatment with troglitazone caused comparable decreases in the metabolic parameters and HOMA index, but did not change casual or 24 h blood pressure (0.8 +/- 3.4/0.8 +/- 2.1 and 1.5 +/- 2.4/ 1.0 +/- 1.9 mmHg, respectively)."( Effects of a low-energy diet and an insulin-sensitizing agent on ambulatory blood pressure in overweight hypertensive patients.
Kawano, Y; Minami, J; Okuda, N; Omae, T; Takishita, S, 2000
)
0.65
"Treatment with troglitazone increased apoptosis and decreased polyamine content and ornithine decarboxylase (ODC) activity in the colonic mucosa of rats treated with AOM."( Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats.
Hosokawa, M; Kohno, H; Okumura, A; Takashima, S; Tanaka, T; Yamaguchi, N; Yoshitani , S, 2001
)
2.09
"Treatment with troglitazone (20 microM) decreased the expression of cyclin D1, heparin-binding epidermal growth factor-like growth factor (HB-EGF) and amphiregulin and suppressed the promoter activities of cyclin D1 and HB-EGF."( PPARgamma agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells.
Hiraoka, S; Kitamura, S; Kiyohara, T; Matsuzawa, Y; Miyazaki, Y; Nagasawa, Y; Shinomura, Y; Takakura, R; Toyota, M, 2001
)
0.65
"Post-treatment with troglitazone, a potent and specific activator of peroxisome proliferator-activated receptor (PPAR)-gamma attenuated the cell death of cerebellar granule neurons, triggered by glutamate exposure."( Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons.
Harada, J; Hisamoto, M; Oda, T; Uryu, S, 2002
)
2.07
"Treatment with troglitazone resulted in a significant, specific decrease in type I collagen along with a slight decrease in laminin production in both medium conditions."( Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro.
Johnson, JH; McCarthy, KJ; Routh, RE, 2002
)
2.1

Toxicity

The first thiazolidinedione derivative drug for diabetes, troglitazone, was found to cause fatal hepatotoxicity. The genotype analysis indicated that the metabolic idiosyncrasy resides in the degradation of but not in the production of the toxic metabolites.

ExcerptReferenceRelevance
" Adverse events were minor and similar between treatments."( Coadministration of acetaminophen and troglitazone: pharmacokinetics and safety.
Eastmond, R; Lettis, S; Young, MA, 1998
)
0.57
" This provides a source of excess FAs that enter potentially toxic pathways of nonoxidative metabolism leading to apoptosis of certain tissues."( Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover.
Unger, RH; Zhou, YT, 2001
)
0.31
"The first thiazolidinedione derivative drug for diabetes, troglitazone, was found to cause fatal hepatotoxicity, although it was judged as safe during the clinical trial."( [Evaluation of thiazolidinedione derivative drugs for safety].
Iwata, M; Kobayashi, M, 2001
)
0.55
" Since that review, some new knowledge allows us to better predict that some structural moieties are more likely than others to form drug reactive metabolites that may be involved in causing toxic effects in humans."( Structure toxicity relationships--how useful are they in predicting toxicities of new drugs?
Nelson, SD, 2001
)
0.31
"Troglitazone, an oral antidiabetic drug, was reported to cause adverse hepatic effects in certain individuals, leading to its withdrawal from the market."( Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells.
Ikeda, T; Iwabuchi, H; Nakajima, M; Watanabe, T; Yamamoto, Y; Yamazaki, H; Yokoi, T, 2002
)
2.01
" We studied the effects of TRZ on the hepatotoxicity of carbon tetrachloride (CCl(4)) and acetaminophen (APAP) in rats, both of which exert their toxic effects through bioactivation associated with cytochrome P450 3A (CYP3A) and 2E1 (CYP2E1)."( Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats.
Kaneko, T; Li, J; Qin, LQ; Sato, A; Wang, PY; Wang, Y, 2002
)
1.76
" In addition, we found that rosiglitazone, although less toxic in the study population, was cytotoxic to hepatocytes in some donors (EC(50)<100 microM)."( Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors.
Fackett, A; Hayden, MJ; Hewitt, NJ; Li, AP; Lloyd, S; Sakai, Y; Silber, PM, 2002
)
0.58
" This is further supported by experimental data that demonstrate that troglitazone, alone among the thiazolidinediones, is toxic in hepatocyte cell culture."( Hepatotoxicity of the thiazolidinediones.
Chandramouli, J; Tolman, KG, 2003
)
0.55
" In contrast, rosiglitazone (RSG), in the same group of agents, has no significant toxic effects and now is widely used."( Chaperone proteins involved in troglitazone-induced toxicity in human hepatoma cell lines.
Katoh, M; Maniratanachote, R; Minami, K; Nakajima, M; Yokoi, T, 2005
)
0.61
"Many adverse drug reactions are caused by the cytochrome P450 (CYP) dependent activation of drugs into reactive metabolites."( An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics.
Grossi, P; Kanter, Rd; Monaci, S; Monshouwer, M; Turlizzi, E; Vignati, L, 2005
)
0.33
" Genes that are differentially expressed between the more toxic troglitazone/ciglitazone group and the less toxic rosiglitazone/pioglitazone group are involved in necrotic, apoptotic, and cell proliferative pathways."( Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells.
Blann, E; Dial, S; Dragan, YP; Guo, L; Muskhelishvili, L; Schroth, G; Shi, L; Sun, Y; Zhang, L, 2006
)
0.57
" In summary, our data from cell culture and wound healing experiments suggested p38 MAPK activation as a side effect of thiazolidinediones; however, only troglitazone, but not rosiglitazone, seemed to translate p38 MAPK activation into a PPARgamma-independent induction of VEGF from keratinocytes."( Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated prote
Bachmann, M; Dissmann, JP; Frank, S; Geisslinger, G; Goren, I; Pfeilschifter, J; Sader, R; Schiefelbein, D; Schmidt, H; Seitz, O, 2008
)
0.74
" Another pharmaceutical that is regularly associated with adverse effects on the liver, sometimes leading to acute liver failure, is the widely used non-steroidal anti-inflammatory drug (NSAID) diclofenac."( Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes.
Kling, M; Lauer, B; Mueller, SO; Tuschl, G, 2009
)
0.61
" While the exact mechanism of its toxicity remains unknown, it has been postulated that the formation of toxic reactive metabolites (RMs) may play an important role in the hepatotoxicity of TGZ."( Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity.
Chan, EC; Chui, WK; Ho, HK; New, LS; Saha, S, 2010
)
0.6
"38 microM) was more toxic than TGZ (EC(50)=41."( Direct toxicity effects of sulfo-conjugated troglitazone on human hepatocytes.
Chan, EC; Chui, WK; Ho, HK; New, LS; Saha, S, 2010
)
0.62
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" The genotype analysis, however, indicated that the metabolic idiosyncrasy resides in the degradation of but not in the production of the toxic metabolites of troglitazone."( Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case.
Ikeda, T, 2011
)
0.79
" In case of hepato-toxicity by non-chromane glitazone and their metabolite such as M-3, RM-3, rosiglitazone and pioglitazone; PASS suggest that these chemicals are not apoptic agonist but they are the substrate for CYP enzyme (Phase-I Oxidative Enzyme) and Phase-II conjugating enzymes; interfering with bile acid metabolism rendering bile acid more toxic (cholestasis)."( Structural insight of glitazone for hepato-toxicity: Resolving mystery by PASS.
Dhangar, K; Jagtap, R; Karpoormath, R; Noolvi, M; Patel, H; Rane, RA; Shaikh, MS; Sonawane, Y; Surana, S; Thapliyal, N, 2015
)
0.42
" Moreover, cell lines used in the present study were more sensitive to toxic effects of troglitazone than previously reported."( Development of an optimized cytotoxicity assay system for CYP3A4-mediated metabolic activation via modified piggyBac transposition.
Dai, R; Dai, T; Deng, J; Huang, L; Jia, Y; Jiang, J; Xie, S; Zou, S, 2016
)
0.66
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
"We demonstrated for the first time the in vivo antitumor effects of TGZ in pancreatic cancer without marked adverse effects."( In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer.
Fujita, M; Hasegawa, A; Okamura, N; Yamamori, M, 2017
)
0.73

Pharmacokinetics

No statistically or clinically relevant differences were observed in maximum concentration (Cmax), time to Cmax (tmax), or elimination half-life of troglitazone. There was a slight decrease in acetaminophen glucuronide excretion during administration with trog litazone, although there was a mono- and bi-phasic elimination phase.

ExcerptReferenceRelevance
" Pharmacokinetic parameter estimates [Cl/F (apparent oral clearance), AUC0-24 (area under plasma concentration-time curve), and ratio of AUC for troglitazone to Metabolite 1 and to Metabolite 3] obtained from 84 healthy volunteers and 171 patients with Type II diabetes in 8 studies were analyzed using a graphical method (for race and smoking) or a weighted ANCOVA model incorporating gender, health status (healthy vs Type II diabetes), and formulation as main effects; age, age-by-gender interaction, and body weight as continuous covariates."( Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites.
Abel, R; Alvey, CW; Koup, JR; Loi, CM; Randinitis, EJ; Young, MA, 1997
)
0.75
" Mean day 15 pharmacokinetic parameter values for metabolite 1 and metabolite 3 were similar in the two groups."( Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study.
Kazierad, DJ; Koup, JR; Loi, CM; Randinitis, EJ; Sedman, AJ; Vassos, AB, 1997
)
0.54
" Mean values for maximum concentration (Cmax), time to Cmax (tmax), and area under the concentration-time curve from 0 to 24 hours (AUC0-24) of digoxin on day 10 were similar to those on day 20."( Effect of troglitazone on steady-state pharmacokinetics of digoxin.
Knowlton, PW; Koup, JR; Loi, CM; Randinitis, EJ; Sedman, AJ; Stern, R; Vassos, AB, 1998
)
0.7
" Pharmacological and pharmacokinetic studies of DN-108 were done."( Pharmacological and pharmacokinetic studies of the newly synthesized thiazolidinedione derivative 5-(4-(1-phenyl-1-cyclopropanecarbonylamino)benzyl)-thiazolidine-2 ,4-dio ne.
Hayashibe, M; Ino, Y; Kurumi, M; Matsuzaki, Y; Muta, Y; Nomura, Y; Suzuki, S; Ueda, N, 1998
)
0.3
" No statistically or clinically relevant differences were observed in maximum concentration (Cmax), time to Cmax (tmax), or elimination half-life of troglitazone, its two main metabolites, and acetaminophen or in acetaminophen urinary sulfate excretion, although there was a slight decrease in acetaminophen glucuronide excretion during administration with troglitazone."( Coadministration of acetaminophen and troglitazone: pharmacokinetics and safety.
Eastmond, R; Lettis, S; Young, MA, 1998
)
0.77
" Plasma concentrations of troglitazone and its metabolites were measured and standard pharmacokinetic parameters derived."( Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency.
Ott, P; Ranek, L; Young, MA, 1998
)
0.92
" There were reductions in the maximum observed plasma concentration (Cmax) of troglitazone to 61% of the normal group in the severe group for troglitazone, and twofold increases in sulphate metabolite Cmax in the moderate and severe groups."( Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency.
Ott, P; Ranek, L; Young, MA, 1998
)
0.85
" Pharmacokinetic profiles of EE and NE were determined on day 21 of the second and third cycles."( Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent.
Knowlton, P; Koup, JR; Loi, CM; Sedman, AJ; Stern, R; Vassos, AB, 1999
)
0.71
"Area-moment analysis was used to calculate pharmacokinetic variables."( Pharmacokinetics of the insulin-sensitizing agent troglitazone in cats.
Boudinot, FD; Ferguson, DC; Hoenig, M; Michels, GM, 2000
)
0.56
"For the pharmacokinetic study, a single, 600-mg dose of either controlled-release LA (CRLA) or quick-release LA (QRLA) was administered orally to 12 normal human subjects."( Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid.
Evans, JL; Gavin, LA; Goldfine, ID; Heymann, CJ,
)
0.13
" CL(int,in vivo) was calculated from in vivo pharmacokinetic data using two frequently used mathematical models (the well stirred and dispersion models)."( Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro.
Kagayama, A; Naritomi, Y; Sugiyama, Y; Terashita, S, 2003
)
0.32
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
"The objective of this study was to evaluate a physiologically based pharmacokinetic (PBPK) approach for predicting the plasma concentration-time curves expected after intravenous administration of candidate drugs to rodents."( Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study.
Burton, PS; Crivori, P; Germani, M; Poggesi, I; Rocchetti, M; Smith, ME; Wilson, AG, 2007
)
0.34
" Pharmacokinetic analysis revealed similar T(max) values for troglitazone in both mouse groups, a mono- and bi-phasic elimination phase in PXB and SCID mice, respectively, but a 3- to 5- and 2- to 5-fold higher C(max) and AUC, respectively, in PXB mice."( Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers.
Foster, JR; Gross, G; Jacobsen, M; Kenna, JG; Morikawa, Y; Salmu, J; Sarda, S; Schulz-Utermoehl, T; Wilson, ID, 2012
)
0.84
" These parameters were extrapolated to 100% chimeric mice and subjected to semi-physiological pharmacokinetic modeling using pharmacokinetic parameters for oral administration taken from literature."( Human plasma concentration-time profiles of troglitazone and troglitazone sulfate simulated by in vivo experiments with chimeric mice with humanized livers and semi-physiological pharmacokinetic modeling.
Chijiwa, H; Ito, S; Kamimura, H; Okuzono, T; Suemizu, H; Yamamoto, Y; Yamazaki, H, 2020
)
0.82

Compound-Compound Interactions

ExcerptReferenceRelevance
" Discussion of its putative risks and benefits as well as the barriers to its wider use both in the context of monotherapy and in combination with oral antidiabetic agents is provided."( The use of insulin alone and in combination with oral agents in type 2 diabetes.
Buse, JB, 1999
)
0.3
"Stable-isotope trapping combined with mass spectrometry (MS) neutral loss scanning has recently been developed as a high-throughput method for the in vitro screening of major reactive metabolites."( Rapid detection and characterization of minor reactive metabolites using stable-isotope trapping in combination with tandem mass spectrometry.
Caldwell, GW; Huebert, N; Maher, N; Torres, R; Yan, Z, 2005
)
0.33
" RS5444 did not induce apoptosis but combined with paclitaxel, doubled the apoptotic index compared to that of paclitaxel."( Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1.
Copland, JA; Fujiwara, K; Haugen, BR; Klopper, JP; Kreinest, PA; Kurakata, S; Marlow, LA; Smallridge, RC; Williams, SF; Wong, AK, 2006
)
0.33
"Hepatic uptake carriers of the organic anion-transporting peptide (OATP) family of solute carriers are more and more recognized as being involved in hepatic elimination of many drugs and potentially associated drug-drug interactions."( Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
Brun, ME; Funk, C; Noé, J; Portmann, R, 2007
)
0.34
" This article reviews the clinical data behind the use of metformin in combination with TZDs for the management of diabetes, its impact on vascular health, side effects and potential mechanisms of action for combined use."( Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes.
Elasy, T; Stafford, JM, 2007
)
0.34
" CYP2C8 inhibition-based in vitro and in vivo drug-drug interactions (DDIs) in wild-type and variant CYP2C8s were then predicted."( Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions.
Chen, C; Gao, Y; Liu, D; Wang, H; Zhu, J, 2010
)
0.36
" In this study, we investigated the inhibitory effect of a PPAR-γ agonist in combination with an anticancer agent on MPM cell growth in vitro and in vivo."( In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
Hamada, H; Hamaguchi, N; Higaki, J; Irifune, K; Ito, R; Miyazaki, T; Miyoshi, S, 2010
)
0.6

Bioavailability

Troglitazone-polyvinylpyrrolidone K30 (PVP) solid dispersions (SDs) were prepared with water by a unique closed melting method. Mean bioavailability of orally administered trog litazone was 6.

ExcerptReferenceRelevance
") and various distribution volumes (Vss, V beta and Vc) based on animal data; (2) estimation of the absorption rate constant (ka) from allometric relationship to body weight, and estimation of F value from the predicted AUCp."( Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach.
Enomoto, S; Hosiyama, K; Izumi, T; Nakagawa, T; Sasahara, K; Shibukawa, A; Sugiyama, Y, 1996
)
0.56
" These data were used to define the bioavailability of test compounds and assist in decisions of constructing active analogs."( Competitive particle concentration fluorescence immunoassays for measuring anti-diabetic drug levels in mouse plasma.
Bright, SW; Dominianni, SJ; Fitch, LL; Gold, G; Schmiegel, KK; Tinsley, FC, 1997
)
0.3
" It is rapidly absorbed with an absolute bioavailability of between 40 and 50%."( Clinical pharmacokinetics of troglitazone.
Koup, JR; Loi, CM; Randinitis, E; Vassos, A; Young, M, 1999
)
0.59
"Although prediction of the plasma profile of lipophilic drugs solely on the basis of in vitro data remains an ambitious target, this study shows that the plasma profile of a lipophilic drug can be predicted with appropriate in vitro dissolution data, provided that the absolute bioavailability of the drug is known and the drug has dissolution limited absorption."( Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration.
Dressman, JB; Nicolaides, E; Reppas, C; Symillides, M, 2001
)
0.31
" It has been suggested that the pathogenesis of early diabetic retinopathy may involve a reduced bioavailability or diminished production of NO."( Troglitazone reverses the inhibition of nitric oxide production by high glucose in cultured bovine retinal pericytes.
Kim, J; Oh, YS; Shinn, SH, 2005
)
1.77
" To increase the bioavailability of insoluble troglitazone, troglitazone-polyvinylpyrrolidone K30 (PVP) solid dispersions (SDs) were prepared with water by a unique closed melting method."( Effects of water content in physical mixture and heating temperature on crystallinity of troglitazone-PVP K30 solid dispersions prepared by closed melting method.
Furuyama, N; Hamaura, T; Hasegawa, S; Kusai, A; Terada, K; Yonemochi, E, 2005
)
0.81
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Troglitazone was administered at a dosage of 200 mg twice daily for 12 weeks in 20 poorly controlled NIDDM patients. On the basis of trog litazone pharmacokinetics in healthy cats, as well as on the based of pharmacodynamics of the drug in humans and other animals, a regimen that uses a dosage of 20 to 40 mg/kg adm is suggested.

ExcerptRelevanceReference
" The drug was more effective in a dosage of 400 mg than with 200 mg (the rate of efficacy 46% vs 25%) and more effective in obese patients than in lean patients (46% vs 25%)."( A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus.
Akanuma, Y; Iwamoto, Y; Kajinuma, H; Kasuga, M; Kosaka, K; Kuzuya, T; Shigeta, Y; Takebe, K; Yamanouchi, T; Yoshida, S, 1991
)
0.28
" Furthermore, 2-deoxyglucose uptake in CS-045-treated adipocytes was increased and the insulin dose-response curve was shifted to the left."( Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
Fujiwara, T; Horikoshi, H; Ushiyama, I; Yoshioka, S; Yoshioka, T, 1988
)
0.27
" These methodologies will be useful for predicting the human pharmacokinetics after oral dosing from animal data."( Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach.
Enomoto, S; Hosiyama, K; Izumi, T; Nakagawa, T; Sasahara, K; Shibukawa, A; Sugiyama, Y, 1996
)
0.56
"To introduce troglitazone (CS-045, Rezulin), a new oral antidiabetic agent and discuss its pharmacology, therapeutics, pharmacokinetics, dosing guidelines, adverse effects, drug interactions, and clinical efficacy."( Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
Campbell, LK; Campbell, RK; Johnson, MD, 1998
)
2.11
"The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of troglitazone are reviewed."( Troglitazone: an antidiabetic agent.
Chen, C, 1998
)
1.96
" Dose-response clonogenic assays of the PC-3 prostate cancer cell line with troglitazone showed an antiproliferative effect (ED50, 3 x 10(-7) M) and other PPARgamma ligands (BRL49653: ED50, 8 x 10(-8) M; 15-deoxy-delta12,14-prostaglandin J2: ED50, 2 x 10(-6) M; ciglitizone: ED50, not reached; indomethacin: ED50, not reached) showed similar effects."( Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.
Asou, H; Holden, S; Koeffler, HP; Koshizuka, K; Kubota, T; Miyoshi, I; Said, JW; Williamson, EA, 1998
)
0.77
"Troglitazone was administered at a dosage of 200 mg twice daily for 12 weeks in 20 poorly controlled NIDDM patients."( Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients.
Kobayashi, I; Mori, M; Sato, N; Shimizu, H; Shimomura, Y; Tsuchiya, T, 1998
)
3.19
" Finally, 63 was found to normalize glycemia when dosed at 3 mg/kg bid po in the Zucker diabetic fatty rat model of type 2 diabetes."( N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
Blanchard, SG; Boswell, EG; Brown, KK; Charifson, PS; Cobb, JE; Collins, JL; Cooper, JP; Dezube, M; Henke, BR; Hull-Ryde, EA; Lake, DH; Lenhard, JM; Oliver, W; Oplinger, J; Parks, DJ; Pentti, M; Plunket, KD; Tong, WQ, 1998
)
0.3
" Dose-response relationships for both of the TZDs were also determined using the 24-h treatment time point."( A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation.
Burris, TP; Cryan, E; Demarest, KT; Osborne, MC; Pelton, PD; Zhou, L, 1999
)
0.3
"This study evaluated the steady-state pharmacokinetics and dose proportionality of troglitazone, metabolite 1 (sulfate conjugate), and metabolite 3 (quinone metabolite) following administration of daily oral doses of 200, 400, and 600 mg troglitazone for 7 days (per dosing period) to 21 subjects."( Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites.
Alvey, CW; Koup, JR; Loi, CM; Randinitis, EJ; Sedman, AJ; Vassos, AB, 1999
)
0.77
" The pharmacokinetics of troglitazone are linear over the clinical dosage range of 200 to 600 mg once daily."( Clinical pharmacokinetics of troglitazone.
Koup, JR; Loi, CM; Randinitis, E; Vassos, A; Young, M, 1999
)
0.9
" Four days before necropsy, mice were dosed with bromodeoxyuridine (BrdU) using osmotic pumps."( Troglitazone-induced heart and adipose tissue cell proliferation in mice.
Breider, MA; de la Iglesia, FA; Gough, AW; Haskins, JR; Sobocinski, G,
)
1.57
" Differences between products (both in vitro or in vivo) were less pronounced than differences due to media composition (in vitro) or dosing conditions (in vivo)."( Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data.
Dressman, JB; Efthymiopoulos, C; Galia, E; Nicolaides, E; Reppas, C, 1999
)
0.3
" PPAR-gamma ligands significantly inhibited VEGF-induced migration and proliferation in both cell types and tube formation of CEC in a dose-response manner."( Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization.
Hangai, M; He, S; Hinton, DR; Hsueh, WA; Ishibashi, T; Kim, S; Law, RE; Murata, T; Ryan, SJ; Xi, XP, 2000
)
0.31
" On the basis of troglitazone pharmacokinetics in healthy cats, as well as on the basis of pharmacodynamics of the drug in humans and other animals, a regimen that uses a dosage of 20 to 40 mg/kg administered orally once or twice per day to cats will produce plasma concentrations of the insulin-sensitizing agent that have been documented to be effective in humans."( Pharmacokinetics of the insulin-sensitizing agent troglitazone in cats.
Boudinot, FD; Ferguson, DC; Hoenig, M; Michels, GM, 2000
)
0.9
" Our study demonstrates that troglitazone, albeit at a dosage 10 to 15 times higher than that in humans, not only prevents but also reverses the metabolic derangement and histopathologic changes in genetically determined obese diabetes."( Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
Akiyama, T; Fukumitsu, KI; Jia, DM; Nakamura, H; Otsuki, M; Tabaru, A, 2000
)
2.04
" In this study, Gunn rats, which are hereditarily deficient in the UGT1 family of UGT isozymes, and Wistar rats, the parent strain of Gunn rats, were treated with troglitazone for 3 months at dose levels of 0, 100 or 400 mg/kg to investigate two possibilities: first, whether the genetic deficiency in UGT1s induces an alteration of the metabolic profile of troglitazone followed by liver dysfunction, and second, whether the dosing of troglitazone to Gunn rats which show hyperbilirubinemia result in liver dysfunction."( Effect of troglitazone on the liver of a Gunn rat model of genetic enzyme polymorphism.
Furukawa, T; Manabe, S; Ohashi, Y; Sharyo, S; Takaoka, M; Watanabe, T; Yasuda, M, 2000
)
0.91
"The thiazolidinedione troglitazone, at a dosage of 400 mg/d, is effective when used in combination with sulfonylurea and metformin."( The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
Foyt, HL; Ghazzi, MN; Owens-Grillo, JK; Valiquett, TR; Whitcomb, RW; Yale, JF, 2001
)
0.89
"Two randomized, two-period crossover studies were conducted to evaluate the effects of repeat oral dosing of troglitazone (Study I) and pioglitazone (Study II) on the pharmacokinetics of plasma HMG-CoA reductase inhibitors following multiple oral doses of simvastatin and of simvastatin on the plasma pharmacokinetics of troglitazone (Study I) in healthy subjects."( Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects.
Amin, RD; Dilzer, S; Gagliano, K; Kuznetsova, O; Lasseter, KC; Liu, L; Musser, B; Prueksaritanont, T; Roadcap, BA; Rogers, JD; Vega, JM; Zhao, J, 2001
)
0.8
"To clarify the dose-response effects of troglitazone on insulin sensitivity and beta-cell function, we examined the effects of high-dose troglitazone (100 mg/day per animal, administered as a food admixture) on glucose and insulin metabolism in hyperinsulinemic Watanabe heritable hyperlipidemic (WHHL) rabbits, and compared the results with our previous results with low-dose troglitazone (10 mg /day per animal)."( Effects of high-dose troglitaz one on insulin sensitivity and beta-cell function in Watanabe heritable hyperlipidemic rabbits.
Fan, P; Horikoshi, H; Mei, J; Saku, K; Shiomi, M; Tanaka, H; Tsujita, Y; Zhang, B,
)
0.4
"Troglitazone showed a potent dose-response effect on the growth inhibition of six pancreatic cancer cell lines, which were suppressed to less than 50% of control at the concentration of 10 microM."( Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone.
Kawa, S; Kiyosawa, K; Nakayama, K; Nikaido, T; Unno, H; Usuda, N, 2002
)
1.98
" When multiple dosages of a drug were tested, the results of the highest approved dosage were used."( Oral antihyperglycemic therapy for type 2 diabetes: scientific review.
Inzucchi, SE, 2002
)
0.31
" Previous studies in our laboratory have shown a large interindividual variation between different donors in cytotoxicity after dosing with TGZ."( Identification of glutathione conjugates of troglitazone in human hepatocytes.
Fackett, A; Li, AP; Lloyd, S; McClellan, HA; Prabhu, S; Silber, PM; Terrell, CM, 2002
)
0.58
" To further our understanding of these processes and to discriminate between different PPAR mediated signalling pathways, a proteomic approach has been undertaken to identify changes in protein expression patterns in Sprague Dawley rat liver following dosing with a PPARalpha agonist (Wyeth 14643), a PPARgamma agonist (Troglitazone) and a compound with mixed PPARalpha/gamma agonist activity (SB-219994)."( Protein expression changes in the Sprague Dawley rat liver proteome following administration of peroxisome proliferator activated receptor alpha and gamma ligands.
Bryant, D; Bugelski, P; Camilleri, P; Cutler, P; Hayes, W; Holbrook, JD; Kramer, K; Lord, PG; Man, WJ; White, IR; Wood, J, 2003
)
0.49
" The prandial glucose regulator repaglinide has been studied in combination with metformin (an inhibitor of hepatic glucose production), neutral protamine Hagedorn (NPH)-insulin (which has a long duration of effect, but at the risk of early hypoglycaemia and late hyperglycaemia in the dosing interval) and three thiazolidinediones (TZDs--troglitazone, rosiglitazone and pioglitazone, which stimulate nuclear receptors to increase insulin sensitivity and reduce insulin resistance) in patients whose diabetes was inadequately controlled by previous monotherapy or combination therapy."( Repaglinide in combination therapy.
Moses, R, 2002
)
0.49
" However, a significant proportion of women with PCOS fail to ovulate with the use of standard dosage of CC and are called CC-resistant PCOS."( Minireview: Up-date management of non responder to clomiphene citrate in polycystic ovary syndrome.
Abd el-Aal, G; Abdel-Kareem, O; Amin, M; Maruo, T; Moriyama, T; Takekida, S, 2003
)
0.32
" Dose-response studies revealed that STAT5b was inhibited at an approximately 7-fold lower concentration of the PPARgamma ligand troglitazone than was required for activation of PPARgamma, indicating that only a portion of cellular PPARgamma is needed for STAT5b inhibition."( Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b.
Shipley, JM; Waxman, DJ, 2004
)
0.53
" However, there was a significant reduction in insulin dosage with troglitazone treatment (22."( The metabolic effects of troglitazone in patients with diabetes and end-stage renal disease.
Arakaki, R; Bornemann, M; Genadio, V; Mohideen, P; Sugihara, J; Sugihara, V, 2005
)
0.87
" Whereas high dosage of full agonists may expose RA patients to cardiovascular adverse effects, the proof of concept that PPAR agonists have therapeutical relevance to OA may benefit from an epidemiological follow-up of joint lesions in diabetic or hyperlipidemic patients treated for long periods of time with glitazones or fibrates."( [Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].
Bianchi, A; Jouzeau, JY; Koufany, M; Moulin, D; Netter, P; Sebillaud, S, 2008
)
0.35
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
"We found that increasing dosage of the C risk allele at SLC30A8 rs13266634 was significantly associated with higher proinsulin levels at baseline (p = 0."( Association of the SLC30A8 missense polymorphism R325W with proinsulin levels at baseline and after lifestyle, metformin or troglitazone intervention in the Diabetes Prevention Program.
Florez, JC; Goldberg, RB; Jablonski, KA; Kahn, SE; Majithia, AR; Mather, KJ; McAteer, JB, 2011
)
0.58
" Following dosing with troglitazone, there was a loss of the large lipid droplets in the human hepatocytes, a decrease in the amount of lipid as observed in frozen sections of liver stained by Oil-red-O, and a decrease in the expression of two bile acid transporters, BSEP and MRP2."( Differential effect of troglitazone on the human bile acid transporters, MRP2 and BSEP, in the PXB hepatic chimeric mouse.
Foster, JR; Jacobsen, M; Kenna, G; Morikawa, Y; Salmu, J; Schulz-Utermoehl, T; Wilson, ID, 2012
)
1
" Metabonomic analysis, via a combination of untargeted and targeted liquid chromatography-mass spectrometry (LC-MS) and untargeted (1)H NMR spectroscopy-based metabolite profiling, was performed on aqueous (AQ) and organic liver extracts from control (SCID) and chimeric humanized (PXB) mice dosed with troglitazone at 0, 300 and 600 mg/kg/day for seven days."( Endogenous and xenobiotic metabolite profiling of liver extracts from SCID and chimeric humanized mice following repeated oral administration of troglitazone.
Ashton, S; Baker, DR; Barnes, AJ; Hobby, K; Loftus, NJ; Michopoulos, F; Spagou, K; Wilson, ID, 2014
)
0.78
" The biotransformation, hepatic transporter and blood chemistry effects of troglitazone were investigated following 7 days of dosing at 600 mg/kg/day to chimeric murinized or humanized FRG mice, Mo-FRG and Hu-FRG mice, respectively."( Troglitazone metabolism and transporter effects in chimeric mice: a comparison between chimeric humanized and chimeric murinized FRG mice.
Abrahamsson, A; Foster, JR; Jacobsen, M; Pickup, K; Randall, K; Samuelsson, K; Sarda, S; Weidolf, L; Wilson, I, 2014
)
2.08
" WT rats dosed with TGZ showed an increase of many bile acid species in plasma on day 1, suggesting the inhibition of Bsep."( Bile Salt Homeostasis in Normal and Bsep Gene Knockout Rats with Single and Repeated Doses of Troglitazone.
Abraham, P; Chen, S; Chen, W; Cheng, Y; Freeden, C; Gan, J; Humphreys, WG; Lai, Y; Nelson, DM; Zhang, Y, 2017
)
0.67
" Peak bile acid increases occurred within 2hours (h) after dosing and returned to baseline values before 24h."( Individual serum bile acid profiling in rats aids in human risk assessment of drug-induced liver injury due to BSEP inhibition.
An, L; Andaya, R; Cepa, S; Maher, J; Morgan, R; Pang, J; Potter, D; Ran, Y; Salphati, L; Schutt, L; Tarrant, J; Wong, L; Zhang, X, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (9)

RoleDescription
hypoglycemic agentA drug which lowers the blood glucose level.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
vasodilator agentA drug used to cause dilation of the blood vessels.
anticonvulsantA drug used to prevent seizures or reduce their severity.
anticoagulantAn agent that prevents blood clotting.
platelet aggregation inhibitorA drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitorAn EC 6.2.1.* (acid-thiol ligase) inhibitor that interferes with the action of a long-chain-fatty-acid--CoA ligase (EC 6.2.1.3).
ferroptosis inhibitorAny substance that inhibits the process of ferroptosis (a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides) in organisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
chromanes
thiazolidinone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
thyroid hormone metabolism II (via conjugation and/or degradation)632
Drug induction of bile acid pathway025

Protein Targets (90)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00450.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency49.28850.004023.8416100.0000AID485290
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency52.73970.125919.1169125.8920AID2549; AID504841
LuciferasePhotinus pyralis (common eastern firefly)Potency32.19680.007215.758889.3584AID624030
acetylcholinesteraseHomo sapiens (human)Potency89.35840.002541.796015,848.9004AID1347397
RAR-related orphan receptor gammaMus musculus (house mouse)Potency14.67640.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency5.64040.173734.304761.8120AID1346859; AID1346924
USP1 protein, partialHomo sapiens (human)Potency56.23410.031637.5844354.8130AID504865
SMAD family member 3Homo sapiens (human)Potency5.64040.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency14.14190.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency35.73750.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency20.08500.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency33.80360.000221.22318,912.5098AID1259243; AID1259247; AID588515; AID588516; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency16.63500.000657.913322,387.1992AID1259377; AID1259378
progesterone receptorHomo sapiens (human)Potency21.58500.000417.946075.1148AID1346795
regulator of G-protein signaling 4Homo sapiens (human)Potency23.77810.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.09640.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency45.81450.000214.376460.0339AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency41.17790.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency14.01150.000817.505159.3239AID1159527; AID1159531; AID588544
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency43.77790.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency59.64270.375827.485161.6524AID588526; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency33.96790.005428.02631,258.9301AID1346982; AID1346985; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency31.74110.000229.305416,493.5996AID1259244; AID1259248; AID588513; AID588514; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency6.91780.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency38.90180.00108.379861.1304AID1645840
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency13.51860.001024.504861.6448AID588534; AID743212
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency0.11250.001019.414170.9645AID588536; AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency6.90130.023723.228263.5986AID743222
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency22.53580.035520.977089.1251AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency45.49000.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency61.13060.001628.015177.1139AID1224843; AID1224895
activating transcription factor 6Homo sapiens (human)Potency54.94100.143427.612159.8106AID1159516
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency35.065019.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency61.64480.057821.109761.2679AID1159526
Histone H2A.xCricetulus griseus (Chinese hamster)Potency126.79300.039147.5451146.8240AID1224845
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency28.18380.354828.065989.1251AID504847
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency19.95260.010039.53711,122.0200AID588547
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency22.53530.000323.4451159.6830AID743065; AID743066; AID743067
heat shock protein beta-1Homo sapiens (human)Potency58.29290.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency14.20700.000627.21521,122.0200AID651741; AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency15.84890.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency13.33590.004611.374133.4983AID624296
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency10.18150.005612.367736.1254AID624032
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency32.18410.251215.843239.8107AID504327
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency10.00000.316212.765731.6228AID881
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency26.95460.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency6.91780.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency6.91780.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency44.62580.002319.595674.0614AID651631; AID651743; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency26.95460.001551.739315,848.9004AID1259244
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency10.00000.00638.235039.8107AID881
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency17.78280.009610.525035.4813AID1479145
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency6.91780.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency6.91780.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)31.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)61.00000.20005.677410.0000AID1473741
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)7.25000.40002.75008.6000AID1209456; AID679483
Bile salt export pumpHomo sapiens (human)IC50 (µMol)13.81430.11007.190310.0000AID1209455; AID1443980; AID1443989; AID1449628; AID1473738; AID1674183; AID681139
Carbonic anhydrase 2Homo sapiens (human)IC50 (µMol)0.97000.00021.10608.3000AID625236
Adenosine receptor A3Homo sapiens (human)IC50 (µMol)5.20800.00001.89408.5470AID625196
Adenosine receptor A3Homo sapiens (human)Ki2.94300.00000.930610.0000AID625196
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)4.00000.00002.800510.0000AID625248
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)5.20800.00021.874210.0000AID625196
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki2.94300.00010.949010.0000AID625196
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)55.00000.00053.49849.7600AID440905
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)Ki10.90000.00081.09276.0000AID662855
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)Ki4.80000.00190.55334.8000AID662853
Amine oxidase [flavin-containing] AHomo sapiens (human)Ki10.50000.00192.379710.0000AID662852
Thromboxane-A synthase Homo sapiens (human)IC50 (µMol)2.96600.00091.230410.0000AID625229
Amine oxidase [flavin-containing] BHomo sapiens (human)IC50 (µMol)2.07000.00001.89149.5700AID1917380; AID501302
Amine oxidase [flavin-containing] BHomo sapiens (human)Ki9.50000.00061.777110.0000AID662854
Mitogen-activated protein kinase 1Homo sapiens (human)IC50 (µMol)1.23800.00031.68789.2000AID625181
Indoleamine 2,3-dioxygenase 1Mus musculus (house mouse)IC50 (µMol)61.00000.00601.625110.0000AID717846
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)IC50 (µMol)1.03000.00501.205110.0000AID1237265; AID1419241; AID223558; AID276984; AID662550; AID699016
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)Ki0.31680.00000.37905.6000AID1373899; AID157268; AID157275; AID1680134; AID1865956
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)1.31200.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.83500.00030.769310.0000AID625217
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)5.20800.00001.819410.0000AID625196
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki2.94300.00000.965010.0000AID625196
Forkhead box protein M1Homo sapiens (human)Ki0.05200.05200.09750.1430AID1727628
ATP-binding cassette sub-family C member 8Homo sapiens (human)IC50 (µMol)1.28500.00431.07038.2000AID223558
ATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)IC50 (µMol)1.28500.00431.36868.2000AID223558
Indoleamine 2,3-dioxygenase 2Mus musculus (house mouse)IC50 (µMol)4.50001.50005.08758.2000AID717845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor subfamily 1 group I member 2Homo sapiens (human)EC50 (µMol)15.80000.00203.519610.0000AID1215086; AID1215087; AID1215094
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)EC50 (µMol)0.78000.00001.262610.0000AID141913
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)EC50 (µMol)0.78000.00000.764610.0000AID141913
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)EC50 (µMol)0.78000.00000.990510.0000AID141913
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)EC50 (µMol)0.78000.00001.052810.0000AID141913
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)EC50 (µMol)0.78000.00001.160510.0000AID141913
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)EC50 (µMol)1.10000.00000.992210.0000AID1510956; AID157124; AID157264; AID1650501; AID1701629; AID1865957; AID1893226; AID223547; AID223555; AID276984; AID404402; AID648786; AID655422; AID662544; AID663287; AID688611; AID696368; AID765266; AID91246
Peroxisome proliferator-activated receptor gammaMus musculus (house mouse)EC50 (µMol)0.89000.00031.654210.0000AID141913; AID596248
Mitogen-activated protein kinase 14Homo sapiens (human)EC50 (µMol)1.00000.00521.51415.9000AID596248
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)Km58.00004.49006.51339.0000AID624630
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)Fold activation3.16003.16003.16003.1600AID157117
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)Fold activation1.12001.12001.12001.1200AID156310
UDP-glucuronosyltransferase 1A10Homo sapiens (human)Km11.00002.74004.21005.6800AID624631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (585)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
negative regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
steroid metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of gene expressionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic catabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic transportNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1-6Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1-6Homo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
liver developmentUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
bilirubin conjugationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
acute-phase responseUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to nutrientUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
animal organ regenerationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to lipopolysaccharideUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
retinoic acid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
response to starvationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
negative regulation of steroid metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavone metabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
flavonoid glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
xenobiotic glucuronidationUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
biphenyl catabolic processUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to ethanolUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to glucocorticoid stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cellular response to estradiol stimulusUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
prostaglandin biosynthetic processThromboxane-A synthase Homo sapiens (human)
icosanoid metabolic processThromboxane-A synthase Homo sapiens (human)
cyclooxygenase pathwayThromboxane-A synthase Homo sapiens (human)
intracellular chloride ion homeostasisThromboxane-A synthase Homo sapiens (human)
response to ethanolThromboxane-A synthase Homo sapiens (human)
positive regulation of vasoconstrictionThromboxane-A synthase Homo sapiens (human)
response to fatty acidThromboxane-A synthase Homo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of macrophage chemotaxisMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of macrophage proliferationMitogen-activated protein kinase 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 1Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 1Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 1Homo sapiens (human)
chemotaxisMitogen-activated protein kinase 1Homo sapiens (human)
DNA damage responseMitogen-activated protein kinase 1Homo sapiens (human)
signal transductionMitogen-activated protein kinase 1Homo sapiens (human)
chemical synaptic transmissionMitogen-activated protein kinase 1Homo sapiens (human)
learning or memoryMitogen-activated protein kinase 1Homo sapiens (human)
insulin receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationMitogen-activated protein kinase 1Homo sapiens (human)
Schwann cell developmentMitogen-activated protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylationMitogen-activated protein kinase 1Homo sapiens (human)
cytosine metabolic processMitogen-activated protein kinase 1Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 1Homo sapiens (human)
androgen receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
regulation of cellular pHMitogen-activated protein kinase 1Homo sapiens (human)
thyroid gland developmentMitogen-activated protein kinase 1Homo sapiens (human)
regulation of protein stabilityMitogen-activated protein kinase 1Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseMitogen-activated protein kinase 1Homo sapiens (human)
regulation of stress-activated MAPK cascadeMitogen-activated protein kinase 1Homo sapiens (human)
mammary gland epithelial cell proliferationMitogen-activated protein kinase 1Homo sapiens (human)
cellular response to amino acid starvationMitogen-activated protein kinase 1Homo sapiens (human)
cellular response to reactive oxygen speciesMitogen-activated protein kinase 1Homo sapiens (human)
response to nicotineMitogen-activated protein kinase 1Homo sapiens (human)
ERBB signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
outer ear morphogenesisMitogen-activated protein kinase 1Homo sapiens (human)
myelinationMitogen-activated protein kinase 1Homo sapiens (human)
response to exogenous dsRNAMitogen-activated protein kinase 1Homo sapiens (human)
steroid hormone mediated signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
negative regulation of cell differentiationMitogen-activated protein kinase 1Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
thymus developmentMitogen-activated protein kinase 1Homo sapiens (human)
progesterone receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
T cell receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
B cell receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 1Homo sapiens (human)
regulation of cytoskeleton organizationMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of telomerase activityMitogen-activated protein kinase 1Homo sapiens (human)
Bergmann glial cell differentiationMitogen-activated protein kinase 1Homo sapiens (human)
long-term synaptic potentiationMitogen-activated protein kinase 1Homo sapiens (human)
face developmentMitogen-activated protein kinase 1Homo sapiens (human)
lung morphogenesisMitogen-activated protein kinase 1Homo sapiens (human)
trachea formationMitogen-activated protein kinase 1Homo sapiens (human)
labyrinthine layer blood vessel developmentMitogen-activated protein kinase 1Homo sapiens (human)
cardiac neural crest cell development involved in heart developmentMitogen-activated protein kinase 1Homo sapiens (human)
ERK1 and ERK2 cascadeMitogen-activated protein kinase 1Homo sapiens (human)
response to epidermal growth factorMitogen-activated protein kinase 1Homo sapiens (human)
cellular response to cadmium ionMitogen-activated protein kinase 1Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 1Homo sapiens (human)
caveolin-mediated endocytosisMitogen-activated protein kinase 1Homo sapiens (human)
regulation of Golgi inheritanceMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of telomere cappingMitogen-activated protein kinase 1Homo sapiens (human)
regulation of early endosome to late endosome transportMitogen-activated protein kinase 1Homo sapiens (human)
cell surface receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 1Homo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of cholesterol effluxPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
long-chain fatty acid transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of osteoblast differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of receptor signaling pathway via STATPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of low-density lipoprotein receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of MAP kinase activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adiponectin secretionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stressPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of connective tissue replacement involved in inflammatory response wound healingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
placenta developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of blood pressurePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of lipid storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of angiogenesisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
monocyte differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
epithelial cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to lipidPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
glucose homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
mRNA transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipoprotein transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
innate immune responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell fate commitmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell maturationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
rhythmic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
white fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of SMAD protein signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cholesterol transporter activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of mitochondrial fissionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of extracellular matrix assemblyPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cellular response to transforming growth factor beta stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adipose tissue developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular endothelial cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of hepatocyte apoptotic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of ATP biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transformation of host cell by virusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to hypoxiaPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
heart developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
epidermis developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to starvationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of cellular ketone metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid beta-oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of appetitePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to insulinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
circadian regulation of gene expressionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
behavioral response to nicotinePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipoprotein metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to ethanolPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of blood pressurePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of glycolytic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nitric oxide metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of lipid biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
enamel mineralizationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to fructose stimulusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid transportPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of cell cycleForkhead box protein M1Homo sapiens (human)
G2/M transition of mitotic cell cycleForkhead box protein M1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIForkhead box protein M1Homo sapiens (human)
DNA repairForkhead box protein M1Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorForkhead box protein M1Homo sapiens (human)
positive regulation of cell population proliferationForkhead box protein M1Homo sapiens (human)
negative regulation of stress-activated MAPK cascadeForkhead box protein M1Homo sapiens (human)
negative regulation of DNA-templated transcriptionForkhead box protein M1Homo sapiens (human)
positive regulation of DNA-templated transcriptionForkhead box protein M1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIForkhead box protein M1Homo sapiens (human)
regulation of Ras protein signal transductionForkhead box protein M1Homo sapiens (human)
regulation of reactive oxygen species metabolic processForkhead box protein M1Homo sapiens (human)
positive regulation of double-strand break repairForkhead box protein M1Homo sapiens (human)
regulation of cell population proliferationForkhead box protein M1Homo sapiens (human)
regulation of transcription by RNA polymerase IIForkhead box protein M1Homo sapiens (human)
intracellular glucose homeostasisATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium ion transportATP-binding cassette sub-family C member 8Homo sapiens (human)
female pregnancyATP-binding cassette sub-family C member 8Homo sapiens (human)
memoryATP-binding cassette sub-family C member 8Homo sapiens (human)
visual learningATP-binding cassette sub-family C member 8Homo sapiens (human)
response to pHATP-binding cassette sub-family C member 8Homo sapiens (human)
response to xenobiotic stimulusATP-binding cassette sub-family C member 8Homo sapiens (human)
response to zinc ionATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of low-density lipoprotein particle clearanceATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of angiogenesisATP-binding cassette sub-family C member 8Homo sapiens (human)
response to lipopolysaccharideATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of tumor necrosis factor productionATP-binding cassette sub-family C member 8Homo sapiens (human)
response to insulinATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of potassium ion transportATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of insulin secretionATP-binding cassette sub-family C member 8Homo sapiens (human)
neuromuscular processATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of glial cell proliferationATP-binding cassette sub-family C member 8Homo sapiens (human)
glutamate secretion, neurotransmissionATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of neuroblast migrationATP-binding cassette sub-family C member 8Homo sapiens (human)
cellular response to organic substanceATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium ion transmembrane transportATP-binding cassette sub-family C member 8Homo sapiens (human)
inorganic cation transmembrane transportATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of uterine smooth muscle relaxationATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of tight junction disassemblyATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of blood-brain barrier permeabilityATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium ion import across plasma membraneATP-binding cassette sub-family C member 8Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 8Homo sapiens (human)
action potentialATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to hypoxiaATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to ischemiaATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ventricular cardiac muscle tissue developmentATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
glucose metabolic processATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
apoptotic processATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
determination of adult lifespanATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to xenobiotic stimulusATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to estradiolATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to ATPATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to testosteroneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
regulation of membrane potentialATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
negative regulation of insulin secretionATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
regulation of insulin secretionATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
nervous system processATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
CAMKK-AMPK signaling cascadeATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
cellular response to nicotineATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
cellular response to glucose stimulusATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
cellular response to tumor necrosis factorATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
potassium ion transmembrane transportATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
inorganic cation transmembrane transportATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
regulation of presynaptic membrane potentialATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
positive regulation of protein localization to plasma membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to resveratrolATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
potassium ion import across plasma membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
regulation of monoatomic ion transmembrane transportATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipopolysaccharideMitogen-activated protein kinase 14Homo sapiens (human)
DNA damage checkpoint signalingMitogen-activated protein kinase 14Homo sapiens (human)
cell morphogenesisMitogen-activated protein kinase 14Homo sapiens (human)
cartilage condensationMitogen-activated protein kinase 14Homo sapiens (human)
angiogenesisMitogen-activated protein kinase 14Homo sapiens (human)
osteoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
placenta developmentMitogen-activated protein kinase 14Homo sapiens (human)
response to dietary excessMitogen-activated protein kinase 14Homo sapiens (human)
chondrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusMitogen-activated protein kinase 14Homo sapiens (human)
glucose metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 14Homo sapiens (human)
chemotaxisMitogen-activated protein kinase 14Homo sapiens (human)
signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
skeletal muscle tissue developmentMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myotube differentiationMitogen-activated protein kinase 14Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 14Homo sapiens (human)
fatty acid oxidationMitogen-activated protein kinase 14Homo sapiens (human)
platelet activationMitogen-activated protein kinase 14Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 14Homo sapiens (human)
osteoclast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 14Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
response to muramyl dipeptideMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of interleukin-12 productionMitogen-activated protein kinase 14Homo sapiens (human)
response to insulinMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of hippo signalingMitogen-activated protein kinase 14Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusMitogen-activated protein kinase 14Homo sapiens (human)
response to muscle stretchMitogen-activated protein kinase 14Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of protein import into nucleusMitogen-activated protein kinase 14Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of erythrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
glucose importMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of glucose importMitogen-activated protein kinase 14Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
stem cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
striated muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationMitogen-activated protein kinase 14Homo sapiens (human)
bone developmentMitogen-activated protein kinase 14Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipoteichoic acidMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to ionizing radiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of brown fat cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 14Homo sapiens (human)
stress-induced premature senescenceMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to virusMitogen-activated protein kinase 14Homo sapiens (human)
regulation of synaptic membrane adhesionMitogen-activated protein kinase 14Homo sapiens (human)
regulation of cytokine production involved in inflammatory responseMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast fusionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
lipid metabolic processUDP-glucuronosyltransferase 1A10Homo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A10Homo sapiens (human)
flavone metabolic processUDP-glucuronosyltransferase 1A10Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A10Homo sapiens (human)
liver developmentUDP-glucuronosyltransferase 1A10Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (169)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1-6Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1-6Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1-6Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1-6Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1-6Homo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme inhibitor activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
steroid bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
monooxygenase activityThromboxane-A synthase Homo sapiens (human)
thromboxane-A synthase activityThromboxane-A synthase Homo sapiens (human)
iron ion bindingThromboxane-A synthase Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygenThromboxane-A synthase Homo sapiens (human)
heme bindingThromboxane-A synthase Homo sapiens (human)
12-hydroxyheptadecatrienoic acid synthase activityThromboxane-A synthase Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityThromboxane-A synthase Homo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
phosphotyrosine residue bindingMitogen-activated protein kinase 1Homo sapiens (human)
DNA bindingMitogen-activated protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 1Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 1Homo sapiens (human)
protein bindingMitogen-activated protein kinase 1Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 1Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityMitogen-activated protein kinase 1Homo sapiens (human)
phosphatase bindingMitogen-activated protein kinase 1Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase 1Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 1Homo sapiens (human)
transcription cis-regulatory region bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
transcription coregulator bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
double-stranded DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
prostaglandin receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
enzyme bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peptide bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
identical protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear retinoid X receptor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
arachidonic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA binding domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
LBD domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
alpha-actinin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
R-SMAD bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
E-box bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
STAT family protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
phosphatase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein domain specific bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
ubiquitin conjugating enzyme bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein-containing complex bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
NFAT protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
MDM2/MDM4 family protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingForkhead box protein M1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificForkhead box protein M1Homo sapiens (human)
protein bindingForkhead box protein M1Homo sapiens (human)
protein kinase bindingForkhead box protein M1Homo sapiens (human)
DNA-binding transcription factor activityForkhead box protein M1Homo sapiens (human)
ATP-activated inward rectifier potassium channel activityATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium channel activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 8Homo sapiens (human)
sulfonylurea receptor activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATP-activated inward rectifier potassium channel activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATPase-coupled monoatomic cation transmembrane transporter activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ADP bindingATP-binding cassette sub-family C member 8Homo sapiens (human)
transmembrane transporter bindingATP-binding cassette sub-family C member 8Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 8Homo sapiens (human)
voltage-gated potassium channel activityATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
protein bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ATP bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ATP-activated inward rectifier potassium channel activityATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ATPase-coupled monoatomic cation transmembrane transporter activityATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ankyrin bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
potassium ion bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
heat shock protein bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
transmembrane transporter bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 14Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase 14Homo sapiens (human)
mitogen-activated protein kinase p38 bindingMitogen-activated protein kinase 14Homo sapiens (human)
NFAT protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A10Homo sapiens (human)
protein kinase C bindingUDP-glucuronosyltransferase 1A10Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A10Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A10Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A10Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A10Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (93)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
nucleoplasmNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intermediate filament cytoskeletonNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1-6Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1-6Homo sapiens (human)
intracellular membrane-bounded organelleUDP-glucuronosyltransferase 1-6Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1-6Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
plasma membraneUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
perinuclear region of cytoplasmUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulum chaperone complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
cytochrome complexUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A1 Homo sapiens (human)
endoplasmic reticulumThromboxane-A synthase Homo sapiens (human)
endoplasmic reticulum membraneThromboxane-A synthase Homo sapiens (human)
cytosolThromboxane-A synthase Homo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
extracellular regionMitogen-activated protein kinase 1Homo sapiens (human)
nucleusMitogen-activated protein kinase 1Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 1Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 1Homo sapiens (human)
early endosomeMitogen-activated protein kinase 1Homo sapiens (human)
late endosomeMitogen-activated protein kinase 1Homo sapiens (human)
endoplasmic reticulum lumenMitogen-activated protein kinase 1Homo sapiens (human)
Golgi apparatusMitogen-activated protein kinase 1Homo sapiens (human)
centrosomeMitogen-activated protein kinase 1Homo sapiens (human)
cytosolMitogen-activated protein kinase 1Homo sapiens (human)
cytoskeletonMitogen-activated protein kinase 1Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 1Homo sapiens (human)
caveolaMitogen-activated protein kinase 1Homo sapiens (human)
focal adhesionMitogen-activated protein kinase 1Homo sapiens (human)
pseudopodiumMitogen-activated protein kinase 1Homo sapiens (human)
azurophil granule lumenMitogen-activated protein kinase 1Homo sapiens (human)
synapseMitogen-activated protein kinase 1Homo sapiens (human)
mitotic spindleMitogen-activated protein kinase 1Homo sapiens (human)
ficolin-1-rich granule lumenMitogen-activated protein kinase 1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 1Homo sapiens (human)
nucleusMitogen-activated protein kinase 1Homo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cytosolPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
intracellular membrane-bounded organellePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
receptor complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaMus musculus (house mouse)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleoplasmForkhead box protein M1Homo sapiens (human)
chromatinForkhead box protein M1Homo sapiens (human)
nucleusForkhead box protein M1Homo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 8Homo sapiens (human)
inward rectifying potassium channelATP-binding cassette sub-family C member 8Homo sapiens (human)
synaptic vesicle membraneATP-binding cassette sub-family C member 8Homo sapiens (human)
sarcolemmaATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium ion-transporting ATPase complexATP-binding cassette sub-family C member 8Homo sapiens (human)
membraneATP-binding cassette sub-family C member 8Homo sapiens (human)
acrosomal vesicleATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
nuclear envelopeATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
endosomeATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
plasma membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
inward rectifying potassium channelATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
intercalated discATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
T-tubuleATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
axolemmaATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
presynaptic membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
neuronal cell bodyATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
cell body fiberATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
glutamatergic synapseATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
plasma membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
spindle poleMitogen-activated protein kinase 14Homo sapiens (human)
extracellular regionMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 14Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
nuclear speckMitogen-activated protein kinase 14Homo sapiens (human)
secretory granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
glutamatergic synapseMitogen-activated protein kinase 14Homo sapiens (human)
ficolin-1-rich granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A10Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A10Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A10Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (455)

Assay IDTitleYearJournalArticle
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID318905Activation of PPARgamma in human LNCaP cells assessed as increase in PPARE driven luciferase reporter expression at 10 uM2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1727627Downregulation of FOXM1 expression in human MDA-MB-231 cells at 40 uM after 48 hrs by Western blot analysis relative to control2021European journal of medicinal chemistry, Jan-01, Volume: 209SP1-independent inhibition of FOXM1 by modified thiazolidinediones.
AID1581772Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G0/G1 phase at 45 uM after 72 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 62.2 +/- 2.7 %)2020European journal of medicinal chemistry, Feb-01, Volume: 187New desulfured troglitazone derivatives: Improved synthesis and biological evaluation.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID20733The Tmax values in female wistar rats.1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID223552Transcriptional activation in CV-1 cells expressing hPPARalpha2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.
AID12556The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1215094Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1865958Agonist activity at PPARgamma (unknown origin) assessed as increase in fluorescein labeled PRIP/RAP250 coactivator peptide requirement by Lanthascreen TR-FRET assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Galangin 3-benzyl-5-methylether derivatives function as an adiponectin synthesis-promoting peroxisome proliferator-activated receptor γ partial agonist.
AID1325483Antioxidant activity in 10% C57BL/6J mouse plasma assessed as inhibition of NaOCl-induced lipid oxidation at 30 uM by DPPP-based fluorescence assay2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID188212Compound was tested for antiinflammatory activity by measuring percentage reduction in inflammation at a dose of 100 mg/kg in rats1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
Synthesis and biological activity of novel thiazolidinediones.
AID663292Agonist activity at PPARgamma in human HepG2 cells assessed as downregulation of glucose-6-phosphatase mRNA by RT-PCR analysis2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Polyhydroxylated macrolides from Seimatosporium discosioides and their effects on the activation of peroxisome proliferator-activated receptor gamma.
AID13069The half life value in female wistar rat at 100 mg/kg, p.o. dose1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1419241Competitive displacement of fluorescently labelled PPAR tracer ligand from GST-tagged human PPARgamma ligand binding domain after 1 hr in dark by TR-FRET competitive binding assay2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
PPARγ-sparing thiazolidinediones as insulin sensitizers. Design, synthesis and selection of compounds for clinical development.
AID1215086Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID117887The compound was tested for percent reduction in plasma triglyceride after 6 days of treatment at a dose of 200 mg/kg/day (oral gavage) in mice1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
AID712750Antitumor activity against human LoVo cells assessed as inhibition of cell proliferation after 2 days by MTT assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
AID276983Displacement of tritium labeled ligand from human PPARalpha by SPA assay2006Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24
Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
AID1474080Ratio of drug concentration at steady state in human at 200 to 600 mg, po QD after 24 hrs to IC50 for human MRP4 overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1325477Antioxidant activity in 10% C57BL/6J mouse plasma assessed as inhibition of AAPH-derived peroxyl radicals-induced pyranine consumption at 50 uM2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID540231Dose normalised AUC in dog after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID1325476Antioxidant activity assessed as inhibition of Meo-AMVN-derived peroxyl radicals-induced fucoxanthin consumption at 50 uM2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID1207715Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID1325480Antioxidant activity in 10% C57BL/6J mouse plasma assessed as inhibition of AAPH-derived peroxyl radicals-induced lipid hydroperoxide formation by DPPP-based fluorescence assay2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID189026Percent reduction in blood glucose is evaluated in rat for euglycemic and hypolipidemic activities at a dose of 10 mg/kg1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID596670Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 1 uM on day 8 relative to control2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1701629Agonist activity at PPARgamma LBD (unknown origin) assessed as increase in recruitment of coactivator peptide fluorescein-TRAP220/DRIP by TR-FRET assay
AID1727637Downregulation of SP1 expression in human MDA-MB-231 cells at 80 uM after 24 hrs by Western blot analysis2021European journal of medicinal chemistry, Jan-01, Volume: 209SP1-independent inhibition of FOXM1 by modified thiazolidinediones.
AID127614No significant effect dose level on blood hemoglobin1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.
AID138614The compound was tested in vivo(ob/ob mouse) for intestinal absorption against plasma glucose at a concentration of 200 mg/kg/day.1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes.
AID189535The compound was tested in vivo for Antihyperglycemic activity in Zucker Diabetic fatty rats, activity is expressed as percent reduction of plasma glucose1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID1680152Inhibition of UVB-induced PTGS2 mRNA in human NHEK cells at 1 uM incubated for 24 hrs by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID155856Phosphorylation of eukaryotic initiation factor 2 alpha (eIF2alpha) in PC12 cells, + = Phosphorylation2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Structure-activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID596469Effect on C/EBPbeta mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID111623In vivo activity against serum lipid peroxidation level (s-LPO) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 50 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID157124Activation of peroxisome proliferator activated receptor gamma measured by induction of 50% of maximum alkaline phosphatase activity, transfection assay in CV-1 cells1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1159271Cytotoxicity against human hepatocytes assessed as cell viability at 200 uM after 90 mins by MTT assay relative to control2014European journal of medicinal chemistry, Aug-18, Volume: 83Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds.
AID308874Increase in GLUT4 gene expression in mouse 3T3L1 cells at 3 uM after 2 days relative to beta-actin mRNA expression2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID1727628Binding affinity to recombinant FOXM1 DBD (unknown origin) expressed in Escherichia coli BL21 (DE3) assessed as disruption of FOXM1-DNA complex preincubated for 1.5 hrs followed by DNA addition measured after 20 mins by EMSA2021European journal of medicinal chemistry, Jan-01, Volume: 209SP1-independent inhibition of FOXM1 by modified thiazolidinediones.
AID596669Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 0.3 uM on day 8 relative to control2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID1680149Inhibition of UVB-induced PGE2 level in human NHEK cells at 1 uM incubated for 24 hrs by ELISA2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1451040Displacement of Fluormone-Pan-PPAR Green from human GST-tagged PPARgamma LBD at 10 uM by TR-FRET assay relative to control2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1451041Displacement of Fluormone-Pan-PPAR Green from human GST-tagged PPARdelta LBD at 10 uM by TR-FRET assay relative to control2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Polypharmacology of N
AID13254871-octanol-water partition coefficient, log P of the compound2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID111650Antihyperglycemic activity was determined in obese (ob/ob) mice by po administration at a dose of 10 mg/kg1999Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4
(3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents.
AID1680125Agonist activity at PPARalpha/PPARgamma in human AT-MSC cells assessed as upregulation of HMGCR mRNA at 1 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID1581769Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G0/G1 phase at 45 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 62.2 +/- 0.5 %)2020European journal of medicinal chemistry, Feb-01, Volume: 187New desulfured troglitazone derivatives: Improved synthesis and biological evaluation.
AID1581774Cell cycle arrest in human MDA-MB-231 cells assessed as reduction in accumulation at G2/M phase at 45 uM after 72 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 19.5 +/- 0.5 %)2020European journal of medicinal chemistry, Feb-01, Volume: 187New desulfured troglitazone derivatives: Improved synthesis and biological evaluation.
AID134144Percent reduction of plasma glucose (PG) after 6 days of treatment. It is the mean of standard deviation observed in plasma glucose (PG) in db/db mice at dose of 30 mg/kg/day; NA = Not Active1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID712747Antitumor activity against human LoVo cells assessed as inhibition of cell proliferation after 1 day by MTT assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
AID223547In vitro transactivation using receptor transactivation assay against hPPAR gamma2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
AID1865957Agonist activity at PPARgamma (unknown origin) assessed as increase in fluorescein labeled TRAP220/DRIP-2 coactivator peptide requirement by Lanthascreen TR-FRET assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Galangin 3-benzyl-5-methylether derivatives function as an adiponectin synthesis-promoting peroxisome proliferator-activated receptor γ partial agonist.
AID156308Compound was tested for fold transactivation of human Peroxisome proliferator activated receptor alpha at 50 uM1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID539298Inhibition of glutamate-induced decrease in GSH level in mouse HT22 cells at 1 uM after 24 hrs2010Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23
N,N-Bis-(8-hydroxyquinoline-5-yl methyl)-benzyl substituted amines (HQNBA): peroxisome proliferator-activated receptor (PPAR-γ) agonists with neuroprotective properties.
AID688611Activation of PPARgamma transfected in HEK293 cells after 18 hrs by firefly luciferase reporter gene-based luminescence assay relative to control2011Journal of natural products, Aug-26, Volume: 74, Issue:8
Lignan derivatives from Krameria lappacea roots inhibit acute inflammation in vivo and pro-inflammatory mediators in vitro.
AID15885Calculated partition coefficient (clogP)1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
Novel euglycemic and hypolipidemic agents. 1.
AID134142Percent reduction of plasma glucose (PG) after 6 days of treatment. It is the mean of standard deviation observed in plasma glucose (PG) in db/db mice at dose of 200 mg/kg/day1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID308851Increase in triglyceride levels in mouse 3T3L1 cells at 3 uM2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1159270Cytotoxicity against human hepatocytes assessed as cell viability at 100 uM after 90 mins by MTT assay relative to control2014European journal of medicinal chemistry, Aug-18, Volume: 83Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds.
AID1636456Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 15.2 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID12007The Cmax value in male wistar rat at 100 mg/kg, p.o. dose1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
AID765253Increase of 2-deoxyglucose uptake in mouse 3T3L1 cells using 2-deoxy-D-(2,6-3H)-glucose at 1 uM after 2 hrs by liquid scintillation counting2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Adipogenetic effects of retrofractamide A derivatives in 3T3-L1 cells.
AID648790Agonist activity at PPARgamma in human HepG2 cells assessed as down-regulation of glucose-6-phosphatase at 0.5 to 12.5 uM by real-time PCR method2012Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6
Acetylenic acid analogues from the edible mushroom Chanterelle (Cantharellus cibarius) and their effects on the gene expression of peroxisome proliferator-activated receptor-gamma target genes.
AID1325486Antioxidant activity in 10% C57BL/6J mouse plasma assessed as inhibition of NpEP-derived singlet oxygen-induced lipid oxidation by DPPP-based fluorescence assay2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID1231390Drug absorption in orally dosed human2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Thiazolidine-2,4-dione derivatives: programmed chemical weapons for key protein targets of various pathological conditions.
AID1325478Antioxidant activity in 10% C57BL/6J mouse plasma assessed as inhibition of SIN-1-derived peroxynitrite-induced lipid oxidation at 50 uM by DPPP-based fluorescence assay2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID184088In vivo activity against hypocholesterol (CHOL) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 100 mg/kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID11995Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID136633Percent reduction in area under glucose tolerance curve (AUC) was determined at 100 umol/kg dose of diet in mice; IA = No significant activity1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.
AID308896Decrease in blood free fatty acid levels in KKAy mouse at 100 mg/kg, po after 2 weeks2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID1680146Inhibition of UVB-induced MMP1 level in human NHEK cells at 1 uM incubated for 24 hrs by ELISA2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID223551Binding affinity at human PPAR alpha2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.
AID1215089Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1159263Cytotoxicity against human MCF7 cells assessed as cell viability at 10 uM after 72 hrs by MTS assay in presence of 10% fetal calf serum relative to control2014European journal of medicinal chemistry, Aug-18, Volume: 83Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds.
AID10640Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID308861Increase in adiponectin release in mouse 3T3L1 cells at 30 uM on day 6 by ELISA2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID662854Uncompetitive inhibition of human MAOB expressed in Pichia pastoris2011ACS medicinal chemistry letters, Oct-15, Volume: 3, Issue:1
Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs.
AID123798Percent reduction of plasma glucose after 6 days of treatment (various doses).1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID156310The fold activation against 50 u M Peroxisome proliferator activated receptor alpha (amino acids 167-468)1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID648791Agonist activity at PPARgamma in human HepG2 cells assessed as down-regulation of phosphoenolpyruvate carboxykinase at 0.5 to 12.5 uM by real-time PCR method2012Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6
Acetylenic acid analogues from the edible mushroom Chanterelle (Cantharellus cibarius) and their effects on the gene expression of peroxisome proliferator-activated receptor-gamma target genes.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1680156Agonist activity at PPARalpha/PPARgamma in human NHEK cells assessed as upregulation of ACACB mRNA at 1 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID1680165Agonist activity at PPARalpha/PPARgamma in human AT-MSC cells assessed as upregulation of FADS2 mRNA at 1 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID141904Agonist activity for murine PPAR alpha receptor in transcriptional activation assay; IA means inactive at 10 uM2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID195492Compound was tested in vivo for Antihyperglycemic activity in diabetic rats, activity is expressed as percent reduction of HbA-1c1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
AID624631Drug glucuronidation reaction catalyzed by human recombinant UGT1A102005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID1325484Inhibition of 15-LOX-mediated lipid oxidation in 10% C57BL/6J mouse plasma2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID596248Agonist activity at PPARgamma in mouse 3T3L1 cells2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID1680132Agonist activity at PPARalpha/PPARgamma in human AT-MSC cells assessed as upregulation of adiponectin mRNA at 1 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID276986Activity at human PPARalpha expressed in CV1 cells using GAL4 chimeric system relative to control2006Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24
Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
AID715913Transactivation of PPAR-gamma transfected in HEK293 cells at 10 uM after 24 hrs by luciferase reporter gene assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Ethyl 2,4,6-trihydroxybenzoate is an agonistic ligand for liver X receptor that induces cholesterol efflux from macrophages without affecting lipid accumulation in HepG2 cells.
AID12723Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID223557Transcriptional activation in CV- cells expressing hPPARgamma2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.
AID1159269Cytotoxicity against human LNCAP cells assessed as cell viability at 10 uM after 72 hrs by MTS assay in presence of 10% fetal calf serum relative to control2014European journal of medicinal chemistry, Aug-18, Volume: 83Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID179764In vitro inhibitory activity against rat microsomal lipid peroxidation (m-LPO)1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1581759Antiproliferative activity against human MDA-MB-231 cells in 10% FCS by crystal violet staining based assay2020European journal of medicinal chemistry, Feb-01, Volume: 187New desulfured troglitazone derivatives: Improved synthesis and biological evaluation.
AID648610Ratio of drug level in liver to plasma in rat2012European journal of medicinal chemistry, May, Volume: 51Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study.
AID308876Increase in 2-Deoxyglucose-uptake in mouse 3T3L1 cells at 3 uM by liquid scintillation counter2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID765267Increase of C/EBPdelta mRNA expression in mouse 3T3L1 cells at 1 uM by RT-PCR analysis relative to beta-actin mRNA level2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Adipogenetic effects of retrofractamide A derivatives in 3T3-L1 cells.
AID308894Decrease in blood free fatty acid levels in KKAy mouse at 100 mg/kg, po after 1 week2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID765226Increase of C/EBPbeta mRNA expression in mouse 3T3L1 cells at 1 uM by RT-PCR analysis relative to beta-actin mRNA level2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Adipogenetic effects of retrofractamide A derivatives in 3T3-L1 cells.
AID12848Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID195493Compound was tested in vivo for Antihyperglycemic activity in diabetic rats, activity is expressed as percent reduction of plasma glucose1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
AID596463Effect on aP2 mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID308871Decrease in IL6 gene expression in mouse 3T3L1 cells at 3 uM after 2 days relative to beta-actin mRNA expression2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID404402Agonist activity at PPARgamma receptor by cofactor assay2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Effects of amide constituents from pepper on adipogenesis in 3T3-L1 cells.
AID373867Hepatic clearance in human hepatocytes in absence of fetal calf serum2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
AID139016Percent reduction in plasma triglyceride (TG) after 6 days of treatment. It is the mean of standard deviation observed in plasma triglyceride (TG) in db/db mice at dose of 200 mg/kg/day1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID10859The Tmax value in male wistar rat at 100 mg/kg, p.o. dose1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
AID712746Antitumor activity against human HCT15 cells assessed as inhibition of cell proliferation after 1 day by MTT assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
AID1159262Cytotoxicity against human HCT116 cells assessed as cell viability at 10 uM after 72 hrs by MTS assay in presence of 10% fetal calf serum relative to control2014European journal of medicinal chemistry, Aug-18, Volume: 83Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds.
AID12554The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
AID648614Antiproliferative activity hormone-dependent human MCF7 cells after 24 hrs by luminescent cell viability assay2012European journal of medicinal chemistry, May, Volume: 51Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study.
AID139020Percent reduction in plasma triglyceride (TG) after 6 days of treatment. It is the mean of standard deviation observed in plasma triglyceride (TG) in db/db mice at dose of 30 mg/kg/day; NA = Not Active1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID117703Compound was tested for antidiabetic activity by measuring percentage reduction in triglycerides at a dose of 30 mg/kg1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
Synthesis and biological activity of novel thiazolidinediones.
AID1581762Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by crystal violet staining based assay2020European journal of medicinal chemistry, Feb-01, Volume: 187New desulfured troglitazone derivatives: Improved synthesis and biological evaluation.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID765264Adipogenetic activity in mouse 3T3L1 cells assessed as increase in triglyceride level at 1 uM relative to control2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Adipogenetic effects of retrofractamide A derivatives in 3T3-L1 cells.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID663293Agonist activity at PPARgamma in human HepG2 cells assessed as downregulation of phosphoenolpyruvate carboxykinase mRNA by RT-PCR analysis2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Polyhydroxylated macrolides from Seimatosporium discosioides and their effects on the activation of peroxisome proliferator-activated receptor gamma.
AID276984Displacement of tritium labeled ligand from human PPARgamma by SPA assay2006Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24
Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID138612The compound was tested in vivo(ob/ob mouse) for intestinal absorption against insulin, at a concentration of 200 mg/kg/day.1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes.
AID765266Agonist activity at PPARgamma (unknown origin) by nuclear receptor cofactor assay2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Adipogenetic effects of retrofractamide A derivatives in 3T3-L1 cells.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID596675Induction of adiponectin protein secretion in mouse 3T3L1 cells at 3 uM on day 8 by ELISA relative to control2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID249439Ratio of intensity of phosphorylation of phosphorylated eIF2a to the intensity of the total eIF2a was determined2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation.
AID1581770Cell cycle arrest in human MDA-MB-231 cells assessed as reduction in accumulation at S phase at 45 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 15.7 +/- 0.4 %)2020European journal of medicinal chemistry, Feb-01, Volume: 187New desulfured troglitazone derivatives: Improved synthesis and biological evaluation.
AID308890Effect on blood triglyceride levels in KKAy mouse at 100 mg/kg, po after 2 weeks2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID109738Hypoglycemic activity at dose 50 mg/Kg in KK-mice after peroral administration1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID136644Percent reduction in plasma blood glucose level was evaluated in mice at a dose of 200 mg/kg/day p.o. for 9 days1998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Novel euglycemic and hypolipidemic agents: Part-2. Antioxidant moiety as structural motif.
AID99690lowest concentration at which glucose utilized was greater than or equal to 140% of control value tested in a glucose utilization L6 myocyte in vitro assay1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Substituted tetrahydropyrrolo[2,1-b]oxazol-5(6H)-ones and tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones as hypoglycemic agents.
AID223554Binding affinity towards human peroxidase proliferator activated receptor alpha (hPPARalpha); No binding2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.
AID662853Uncompetitive inhibition of rat MAOA expressed in Pichia pastoris2011ACS medicinal chemistry letters, Oct-15, Volume: 3, Issue:1
Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs.
AID1159265Cytotoxicity against human MDA435 cells assessed as cell viability at 10 uM after 72 hrs by MTS assay in presence of 10% fetal calf serum relative to control2014European journal of medicinal chemistry, Aug-18, Volume: 83Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds.
AID624630Drug glucuronidation reaction catalyzed by human recombinant UGT1A12005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID12724Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID111639In vivo activity against triglycerides (TG) by Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 50 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID765229Increase of GLUT4 mRNA expression in mouse 3T3L1 cells at 1 uM by RT-PCR analysis relative to beta-actin mRNA level2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Adipogenetic effects of retrofractamide A derivatives in 3T3-L1 cells.
AID596450Induction of insulin-stimulated 2-deoxy-D- 2,6-[3H]-glucose uptake in differentiated mouse 3T3L1 cells at 3 uM compound treated for 20 mins with insulin by liquid scintillation counting (Rvb = 100.0 %)2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID12850The Kel value in male wistar rat at 100 mg/kg, p.o. dose1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1215096Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID233277Selectivity ratio for Antihyperglycemic potency dose and No significant effect dose1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.
AID1581773Cell cycle arrest in human MDA-MB-231 cells assessed as reduction in accumulation at S phase at 45 uM after 72 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 13.1 +/- 1.2 %)2020European journal of medicinal chemistry, Feb-01, Volume: 187New desulfured troglitazone derivatives: Improved synthesis and biological evaluation.
AID155853Tested for the intracellular Ca+2 release in PC12 cells; + = Release2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Structure-activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium.
AID503313Antiproliferative activity against human PC3 cells at 15 uM after 120 hrs by MTT assay relative to DMSO2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1325479Antioxidant activity assessed as inhibition of AAPH-derived peroxyl radicals-induced PGR consumption2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID1581784Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at sub-G1 phase at 45 uM after 72 hrs by propidium iodide staining-based flow cytometric analysis2020European journal of medicinal chemistry, Feb-01, Volume: 187New desulfured troglitazone derivatives: Improved synthesis and biological evaluation.
AID596454Effect on adiponectin mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID308880Decrease in blood glucose levels in KKAy mouse at 100 mg/kg, po2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID503296Agonist activity at PPARgamma expressed in HEK293 cells assessed as induction of receptor interaction with steroid receptor coactivator-1 by EYFP based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1198932Induction of p53 protein level in human HepG2 cells at 50 uM upto 24 hrs by immunoblot analysis2015Bioorganic & medicinal chemistry letters, May-01, Volume: 25, Issue:9
Structural insight of glitazone for hepato-toxicity: Resolving mystery by PASS.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1581758Antiproliferative activity against human MCF7 cells in 10% FCS by crystal violet staining based assay2020European journal of medicinal chemistry, Feb-01, Volume: 187New desulfured troglitazone derivatives: Improved synthesis and biological evaluation.
AID717844Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID1727630Inhibition of FOXM1 transcriptional activity in human MDA-MB-231 cells at 40 uM after 12 hrs by luciferase reporter gene assay2021European journal of medicinal chemistry, Jan-01, Volume: 209SP1-independent inhibition of FOXM1 by modified thiazolidinediones.
AID223543Fold activation relative to maximum hPPAR alpha activation obtained with WY-146432002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
AID1917380Inhibition of recombinant human MAO-B2022Bioorganic & medicinal chemistry letters, 11-15, Volume: 76Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors.
AID717840Inhibition of mouse Tdo2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 100 uM after 45 mins by spectrophotometric analysis relative to control2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID419236Induction of preadipocyte differentiation in mouse ST-13 cells assessed as lipid accumulation at 5 uM within 11 days by oil red-staining relative to control2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Identification of nobiletin, a polymethoxyflavonoid, as an enhancer of adiponectin secretion.
AID404404Antidiabetic activity in mouse 3T3L1 cells assessed as enhancement of triglyceride accumulation at 3 uM2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Effects of amide constituents from pepper on adipogenesis in 3T3-L1 cells.
AID1680127Agonist activity at PPARalpha/PPARgamma in human AT-MSC cells assessed as upregulation of ACAT1 mRNA at 1 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1159268Cytotoxicity against human PC3 cells assessed as cell viability at 10 uM after 72 hrs by MTS assay in presence of 10% fetal calf serum relative to control2014European journal of medicinal chemistry, Aug-18, Volume: 83Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds.
AID111624In vivo activity against triglycerides (TG) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 100 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1680166Agonist activity at PPARalpha/PPARgamma in human AT-MSC cells assessed as upregulation of SCD1 mRNA at 1 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID662549Binding affinity to GST-tagged human PPARalpha by TR-FRET analysis2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Total synthesis and dual PPARα/γ agonist effects of amorphastilbol and its synthetic derivatives.
AID1198931Induction of p53 protein level in human HepG2 cells at 50 uM by immunoblot analysis2015Bioorganic & medicinal chemistry letters, May-01, Volume: 25, Issue:9
Structural insight of glitazone for hepato-toxicity: Resolving mystery by PASS.
AID662852Uncompetitive inhibition of human MAOA expressed in Pichia pastoris2011ACS medicinal chemistry letters, Oct-15, Volume: 3, Issue:1
Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs.
AID136640Percent reduction in area under glucose tolerance curve at 300 uM/kg dose in diet of mice.1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.
AID596672Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 10 uM on day 8 relative to control2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID109737Hypoglycemic activity at dose 150 mg/Kg in KK-mice after peroral administration1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID10858The Tmax value in female wistar rat at 100 mg/kg, p.o. dose1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
AID276987Activity at human PPARgamma expressed in CV1 cells by cotransfection assay relative to control2006Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24
Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
AID110045Effective dose for 25% blood glucose decrease in genetically diabetic KKA mice.1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents.
AID1510956Agonist activity at PPARgamma (unknown origin) incubated for 3 to 16 hrs by pathhunter nuclear hormone receptor assay2019ACS medicinal chemistry letters, Jul-11, Volume: 10, Issue:7
Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis.
AID223779Evaluated in vivo for their ability to decrease plasma glucose levels in diabetic C57BL/KsJ db/db mouse at a dose 100 mg/kg/day.(p is partition coefficient)2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
New azolidinediones as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties.
AID503297Agonist activity at PPARgamma expressed in HEK293 cells assessed as induction of receptor interaction with retinoid X-receptor alpha by EYFP based reporter gene assay2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID117701Compound was tested for antidiabetic activity by measuring percentage reduction in plasma glucose at a dose of 30 mg/kg1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
Synthesis and biological activity of novel thiazolidinediones.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1215093Activation of rat PXR expressed in human HepG2 cells up to 46 uM after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1407683Inhibition of recombinant human CYP2C19 expressed in insect cell microsomes at 10 uM using Luciferin-H EGE as substrate preincubated for 20 mins followed by NADPH addition measured after 30 mins by luminometric method2018European journal of medicinal chemistry, Sep-05, Volume: 157Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
AID648613Antiproliferative activity hormone-independent human MDA-MB-231 cells after 24 hrs by luminescent cell viability assay2012European journal of medicinal chemistry, May, Volume: 51Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study.
AID117884The compound was tested for percent reduction in plasma triglyceride after 6 days of treatment at 100 mg/kg/day in mice; not determined1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
AID157275In vitro binding to peroxisome proliferator activated receptor gamma (PPAR gamma) using [3H]-BRL 49653 as radioligand in scintillation proximity assay (SPA)1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID189532The compound was tested for Antihyperlipidemic activity in Zucker Diabetic fatty rats, activity is expressed as percent reduction of NEFAs1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID712758Induction of apoptosis in human HT-29 cells at IC50 by Annexin V-FITC/propidium iodide staining based flow cytometry2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
AID14476The Cmax values in female wistar rats.1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID223549Fold activation relative to maximum activation obtained with rosiglitazone2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
AID19643Partition coefficient (logP)2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Structure-activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium.
AID645239Antiviral activity against Rotavirus SA11 in MA104 cells assessed as inhibition of viral replication after 24 hrs by immunofluorescent assay and Western blotting analysis2012European journal of medicinal chemistry, Apr, Volume: 50Novel triacsin C analogs as potential antivirals against rotavirus infections.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID156775Binding affinity against Peroxisome proliferator activated receptor delta (PPAR delta); Not active1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Synthesis and biological activity of a novel series of indole-derived PPARgamma agonists.
AID156309Fold activation against Peroxisome proliferator activated receptor alpha (50 uM)1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
AID302758Solubility by shake flask method2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Poorly soluble marketed drugs display solvation limited solubility.
AID1636398Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 8.5 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1680150Inhibition of UVB-induced MMP1 mRNA in human NHEK cells at 1 uM incubated for 24 hrs by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID1443989Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell plasma membrane vesicles assessed as reduction in ATP-dependent [3H]-taurocholate uptake in to vesicles preincubated for 10 mins followed by ATP addition measured after 10 to 2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID765230Increase of PPARgamma2 mRNA expression in mouse 3T3L1 cells at 1 uM by RT-PCR analysis relative to beta-actin mRNA level2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Adipogenetic effects of retrofractamide A derivatives in 3T3-L1 cells.
AID117883The compound was tested for percent reduction in plasma glucose after 6 days of treatment at a dose of 200 mg/kg/day (oral gavage) in mice1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID13070The half life value in male wistar rat at 100 mg/kg, p.o. dose1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
AID682108TP_TRANSPORTER: inhibition of estrone-3-sulfate uptake (Estrone-3-sulfate: 9.2 nM) by Troglitazone at a concentration of 10uM in OATP-C-expressing Xenopus oocytes2004Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 32, Issue:3
Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity.
AID195486Compound was tested for Antihyperlipidemic activity, activity is expressed as percent reduction of NEFAs1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
AID738064Induction of differentiation of mouse 3T3L1 cells assessed as lipid accumulation at 10 uM after 8 days by using Oil Red O staining by spectrophotometry relative to control2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Anti-adipogenic diarylheptanoids from Alnus hirsuta f. sibirica on 3T3-L1 cells.
AID765228Increase of aP2 mRNA expression in mouse 3T3L1 cells at 1 uM by RT-PCR analysis relative to beta-actin mRNA level2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Adipogenetic effects of retrofractamide A derivatives in 3T3-L1 cells.
AID17843The Kel values in female wistar rats.1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID1474078Ratio of drug concentration at steady state in human at 200 to 600 mg, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540233Dose normalised AUC in human after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID1215095Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay relative to SR128132011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID111626In vivo activity against hypocholesterol (CHOL) by Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 50 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID308865Increase in adiponectin gene expression in mouse 3T3L1 cells at 3 uM after 2 days relative to beta-actin mRNA expression2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID1650501Partial agonist activity at PPARgamma LBD (unknown origin) assessed as increase in recruitment of coactivator peptide C33 by TR-FRET assay2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Selenium bioisosteric replacement of adenosine derivatives promoting adiponectin secretion increases the binding affinity to peroxisome proliferator-activated receptor δ.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1680134Binding affinity to human recombinant PPARgamma by Cheng-Prusoff equation based competitive binding TR-FRET assay2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID404409Increase in 2-deoxyglucose uptake in mouse 3T3L1 cells at 3 uM by liquid scintillation counter2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Effects of amide constituents from pepper on adipogenesis in 3T3-L1 cells.
AID14913The AUC(0-infinity) values in female wistar rats.1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID223558Binding affinity at human peroxidase proliferator activated receptor gamma (hPPARgamma)2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.
AID155860Concentration required for 50% inhibition of cell proliferation in PC12 cells using sulforhodamine B assay2004Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10
Structure-activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium.
AID1680155Agonist activity at PPARalpha/PPARgamma in human NHEK cells assessed as upregulation of HMGCR mRNA at 1 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID696368Transactivation of GAL4-fused PPARgamma ligand binding domain transfected in human HepG2 cells after 20 hrs by luciferase reporter gene assay2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
Diarylheptanoid glycosides from Tacca plantaginea and their effects on NF-κB activation and PPAR transcriptional activity.
AID91238Agonist activity for Human PPAR alpha receptor in transcriptional activation assay; IA means inactive at 10 uM2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID624648Inhibition of AZT glucuronidation by human recombinant UGT1A62005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID12849The Kel value in female wistar rat at 100 mg/kg, p.o. dose1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
AID223555Binding affinity at human PPAR gamma2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.
AID130064Antihyperglycemic potency dose producing approximately 25% reduction in area under glucose tolerance curve1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID308886Effect on blood triglyceride levels in KKAy mouse at 100 mg/kg, po2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID10675Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID1865949Induction of adiponectin synthesis in human differentiated BMMSC cells measured after 5 days in the presence of IDX induction medium by ELISA2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Galangin 3-benzyl-5-methylether derivatives function as an adiponectin synthesis-promoting peroxisome proliferator-activated receptor γ partial agonist.
AID1893226Agonist activity at human PPAR-gamma expressed in CHO-K1 cells by PathHunter assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Discovery of (
AID141910Agonist activity for murine PPAR delta receptor in transcriptional activation assay; IA means inactive at 10 uM2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID157116Fold activation against Peroxisome proliferator activated receptor gamma (1 uM)1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
AID91243Agonist activity for Human PPAR delta receptor in transcriptional activation assay; IA means inactive at 10 uM2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID308888Effect on blood triglyceride levels in KKAy mouse at 100 mg/kg, po after 1 week2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID308892Decrease in blood free fatty acid levels in KKAy mouse at 100 mg/kg, po2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID223546Fold activation relative to maximum activation obtained with carbacyclin2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
AID662851Inhibition of human histone demethylase LSD1 up to 100 uM2011ACS medicinal chemistry letters, Oct-15, Volume: 3, Issue:1
Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs.
AID712748Antitumor activity against human HT-29 cells assessed as inhibition of cell proliferation after 2 days by MTT assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
AID1474077Drug concentration at steady state in human at 200 to 600 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID157209Inhibition of PTPase activity in rat hepatic membrane at a concentration of 250 uM using pNPP as the substrate2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
New azolidinediones as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties.
AID136642Percent reduction in area under glucose tolerance curve (AUC) was determined at 3000 umol/kg dose of diet in mice1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.
AID596460Effect on GlUT4 mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID91246Agonist activity for Human PPAR gamma receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID1373883Induction of adipogenesis in human bone marrow-derived mesenchymal stem cells assessed as increase in adiponectin production at 1 uM measured on day 5 in presence of IDX by ELISA2018Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5
2-Formyl-komarovicine promotes adiponectin production in human mesenchymal stem cells through PPARγ partial agonism.
AID419245Agonist activity at Gal4-fused human PPARgamma expressed in african green monkey COS1 cells by luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Identification of nobiletin, a polymethoxyflavonoid, as an enhancer of adiponectin secretion.
AID1431849Induction of mitochondrial membrane hyperpolarization in bloodstream trypomastigote stage of wild-type Trypanosoma brucei brucei Lister 427 at 10 uM after 10 mins by TMRE dye based flow cytometry2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Conjugates of 2,4-Dihydroxybenzoate and Salicylhydroxamate and Lipocations Display Potent Antiparasite Effects by Efficiently Targeting the Trypanosoma brucei and Trypanosoma congolense Mitochondrion.
AID699016Inhibition of fluormone binding to human PPARgamma LBD after 2 hrs by competitive fluorescence polarization assay2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Sesquiterpene lactones from Tithonia diversifolia act as peroxisome proliferator-activated receptor agonists.
AID308852Increase in triglyceride levels in mouse 3T3L1 cells at 10 uM2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID111622In vivo activity against serum lipid peroxidation level (s-LPO) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 100 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID1581771Cell cycle arrest in human MDA-MB-231 cells assessed as reduction in accumulation at G2/M phase at 45 uM after 48 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 20.5 +/- 0.6 %)2020European journal of medicinal chemistry, Feb-01, Volume: 187New desulfured troglitazone derivatives: Improved synthesis and biological evaluation.
AID123800The compound was tested for percent reduction of plasma triglyceride after 6 days of treatment.1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID364308Activity at PPARgamma in human Caco-2 cells assessed as luciferase activity at 10 uM relative to control2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
NSAIDs revisited: putative molecular basis of their interactions with peroxisome proliferator-activated gamma receptor (PPARgamma).
AID1159266Cytotoxicity against human MiaPaCa cells assessed as cell viability at 10 uM after 72 hrs by MTS assay in presence of 10% fetal calf serum relative to control2014European journal of medicinal chemistry, Aug-18, Volume: 83Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds.
AID663287Agonist activity at human recombinant PPARgamma expressed in CHO cells cotransfected with pGL3-PPRE3-TK-luc reporter assessed as beta-galactosidase activity at after 24 hrs by luciferase based transactivation assay2012Journal of natural products, Apr-27, Volume: 75, Issue:4
Polyhydroxylated macrolides from Seimatosporium discosioides and their effects on the activation of peroxisome proliferator-activated receptor gamma.
AID765262Adipogenetic activity in mouse 3T3L1 cells assessed as increase in triglyceride level at 3 uM relative to control2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Adipogenetic effects of retrofractamide A derivatives in 3T3-L1 cells.
AID14916The AUC(0-t)values in female wistar rats.1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1474076AUC in human at 200 to 600 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID12006The Cmax value in female wistar rat at 100 mg/kg, p.o. dose1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
AID12555The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
AID1865956Binding affinity to PPARgamma (unknown origin) assessed as inhibition constant by Lanthascreen TR-FRET assay relative to control2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Galangin 3-benzyl-5-methylether derivatives function as an adiponectin synthesis-promoting peroxisome proliferator-activated receptor γ partial agonist.
AID648612Cytotoxicity against human hepatocytes assessed as cell viability at 100 uM after 90 mins by MTT assay relative to control2012European journal of medicinal chemistry, May, Volume: 51Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study.
AID111625In vivo activity against triglycerides (TG) by using Alloxan-induced hyperlipoperoxidemia method in BALB/c mice after peroral administration at 100 mg/Kg dose1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation.
AID540232Dose normalised AUC in monkey after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID243422log (1/Km) value for human liver microsome cytochrome P450 3A42005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID117881The compound was tested for percent reduction in plasma glucose after 6 days of treatment at a dose of 100 mg/kg/day in mice1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
AID648609Cytotoxicity against human hepatocytes assessed as cell viability up to 50 uM after 90 mins by MTT assay2012European journal of medicinal chemistry, May, Volume: 51Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study.
AID765263Adipogenetic activity in mouse 3T3L1 cells assessed as increase in triglyceride level at 0.3 uM relative to control2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Adipogenetic effects of retrofractamide A derivatives in 3T3-L1 cells.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID662550Binding affinity to GST-tagged human PPARgamma by TR-FRET analysis2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Total synthesis and dual PPARα/γ agonist effects of amorphastilbol and its synthetic derivatives.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID596679Induction of insulin-stimulated 2-deoxy-D- 2,6-[3H]-glucose uptake in mouse 3T3L1 cells chronically treated at 3 uM by liquid scintillation counting (Rvb = 100.0 %)2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID1373899Displacement of fluormone Pan-PPAR Green from human GST-tagged PPARgamma-LBD by TR-FRET assay2018Bioorganic & medicinal chemistry, 03-01, Volume: 26, Issue:5
2-Formyl-komarovicine promotes adiponectin production in human mesenchymal stem cells through PPARγ partial agonism.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID765231Increase of adiponectin mRNA expression in mouse 3T3L1 cells at 1 uM by RT-PCR analysis relative to beta-actin mRNA level2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Adipogenetic effects of retrofractamide A derivatives in 3T3-L1 cells.
AID247453Inhibition of human lung cancer cell line (A549) by 50% in sulforhodamine B assay2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation.
AID1674184Toxicity in po dosed human assessed as maximum daily dose2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
AID1159267Cytotoxicity against human HepG2 cells assessed as cell viability at 10 uM after 72 hrs by MTS assay in presence of 10% fetal calf serum relative to control2014European journal of medicinal chemistry, Aug-18, Volume: 83Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds.
AID1237265Agonist activity at PPARgamma (unknown origin)2015Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15
Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1581760Antiproliferative activity against human MDA-MB-453 cells in 10% FCS by crystal violet staining based assay2020European journal of medicinal chemistry, Feb-01, Volume: 187New desulfured troglitazone derivatives: Improved synthesis and biological evaluation.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID501302Inhibition of human recombinant MAO-B after 15 mins2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening.
AID308850Increase in triglyceride levels in mouse 3T3L1 cells at 1 uM2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID645241Cytotoxicity against monkey MA104 cells after 24 hrs2012European journal of medicinal chemistry, Apr, Volume: 50Novel triacsin C analogs as potential antivirals against rotavirus infections.
AID1674183Inhibition of human BSEP expressed in HEK293 cell membrane vesicles assessed as reduction in 3H-TCA uptake incubated for 5 mins by radiodetection method2020Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
AID679483TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurocholate: 1 uM) in liver canalicular membrane vesicle from female rat2001Toxicology, Oct-05, Volume: 167, Issue:1
Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt
AID1159264Cytotoxicity against human MDA-MB-231 cells assessed as cell viability at 10 uM after 72 hrs by MTS assay in presence of 10% fetal calf serum relative to control2014European journal of medicinal chemistry, Aug-18, Volume: 83Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID141913Agonist activity for murine PPAR gamma receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID648786Agonist activity at human PPARgamma expressed in CHO cells co-transfected with pGL3-PPRE3-TK-luc assessed as transactivation after 24 hrs by firefly luciferase reporter gene assay2012Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6
Acetylenic acid analogues from the edible mushroom Chanterelle (Cantharellus cibarius) and their effects on the gene expression of peroxisome proliferator-activated receptor-gamma target genes.
AID717846Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID195487Compound was tested for Antihyperlipidemic activity, activity is expressed as percent reduction of Triglycerides1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.
AID1581761Antiproliferative activity against human Hs578T cells in 10% FCS by crystal violet staining based assay2020European journal of medicinal chemistry, Feb-01, Volume: 187New desulfured troglitazone derivatives: Improved synthesis and biological evaluation.
AID717845Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID12557The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
AID1896153Antiviral activity against HBV infected in human HepG2-hNTCP cells assessed as reduction in HBsAg level preincubated for 2 hrs followed by viral infection for 16 hrs further compound washout and measured after 12 days post infection by ELISA2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Inhibiting Sodium Taurocholate Cotransporting Polypeptide in HBV-Related Diseases: From Biological Function to Therapeutic Potential.
AID655422Transactivation of GAL4-fused PPARgamma LBD expressed in HepG2 cells after 20 hrs by luminescence assay2012Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7
Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii.
AID1215087Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID596245Effect on C/EBPdelta mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1231389Lipophilicity, log P of the compound2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Thiazolidine-2,4-dione derivatives: programmed chemical weapons for key protein targets of various pathological conditions.
AID1680154Agonist activity at PPARalpha/PPARgamma in human NHEK cells assessed as upregulation of FASN mRNA at 1 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID404403Antidiabetic activity in mouse 3T3L1 cells assessed as enhancement of triglyceride accumulation at 1 uM2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Effects of amide constituents from pepper on adipogenesis in 3T3-L1 cells.
AID1636508Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 40.5 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID308882Decrease in blood glucose levels in KKAy mouse at 100 mg/kg, po after 1 week2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID765227Increase of C/EBPalpha mRNA expression in mouse 3T3L1 cells at 1 uM by RT-PCR analysis relative to beta-actin mRNA level2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Adipogenetic effects of retrofractamide A derivatives in 3T3-L1 cells.
AID1325489Plasma concentration in human at 400 mg, po2016Bioorganic & medicinal chemistry letters, 11-15, Volume: 26, Issue:22
Inhibition of plasma lipid oxidation induced by peroxyl radicals, peroxynitrite, hypochlorite, 15-lipoxygenase, and singlet oxygen by clinical drugs.
AID440905Inhibition of PTP1B2009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects.
AID404405Antidiabetic activity in mouse 3T3L1 cells assessed as enhancement of triglyceride accumulation at 10 uM2008Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11
Effects of amide constituents from pepper on adipogenesis in 3T3-L1 cells.
AID596466Effect on C/EBPalpha mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID712749Antitumor activity against human HCT15 cells assessed as inhibition of cell proliferation after 2 days by MTT assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
AID540230Dose normalised AUC in rat after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID1680141Induction of adipogenesis in human AT-MSC assessed as adiponectin secretion in IDX medium incubated for 5 days by ELISA2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID157115Compound was tested for fold transactivation of human Peroxisome proliferator activated receptor gamma at 1 uM1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID596457Effect on PPARgamma2 mRNA expression in mouse 3T3L1 cells at 3 uM on day 8 by RT-PCR relative to beta-actin mRNA expression2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID22760The half life period in female wistar rats.1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID596671Induction of adipogenesis in mouse 3T3L1 cells assessed as increase in triglyceride level at 3 uM on day 8 relative to control2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Structural requirements of flavonoids for the adipogenesis of 3T3-L1 cells.
AID681139TP_TRANSPORTER: increase in dihydrofluorescein intracellular accumulation (dihydrofluorescein: 1 uM) in SK-E2 cells (expressing BSEP)2003Pharmaceutical research, Apr, Volume: 20, Issue:4
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.
AID648611Cmax in human at 600 mg/day2012European journal of medicinal chemistry, May, Volume: 51Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study.
AID1467836Antidiabetic activity in diabetic db/db mouse assessed as time required for improved glucose disposal by oral glucose tolerance test2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3.
AID1680131Induction of adipogenesis in human AT-MSC assessed as adiponectin secretion at 10 uM in IDX medium incubated for 5 days by ELISA (Rvb = 100 +/- 15 pg/ml)2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID665972Cytotoxicity against human PC3 cells after 24 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID1473835Stimulation of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID157117The fold activation against 1 amino acids 174-475)1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
AID662544Transactivation of human PPARgamma expressed in african green monkey CV1 cells by luciferase reporter gene assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Total synthesis and dual PPARα/γ agonist effects of amorphastilbol and its synthetic derivatives.
AID3423Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents.
AID157264Transcriptional activation of peroxisome proliferator activated receptor gamma1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Synthesis and biological activity of a novel series of indole-derived PPARgamma agonists.
AID665971Cytotoxicity against human LNCAP cells after 24 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives.
AID1474079Ratio of drug concentration at steady state in human at 200 to 600 mg, po QD after 24 hrs to IC50 for human MRP3 overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID717843Selectivity ratio of IC50 for mouse Ido1 to IC50 for mouse Ido22012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID157268Binding affinity against Peroxisome proliferator activated receptor gamma (PPAR gamma)1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Synthesis and biological activity of a novel series of indole-derived PPARgamma agonists.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID189533The compound was tested for Antihyperlipidemic activity in Zucker Diabetic fatty rats, activity is expressed as percent reduction of Triglycerides1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID308857Increase in adiponectin release in mouse 3T3L1 cells at 30 uM on day 4 by ELISA2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID662855Uncompetitive inhibition of rat MAOB expressed in Pichia pastoris2011ACS medicinal chemistry letters, Oct-15, Volume: 3, Issue:1
Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678719Metabolic stability in human liver microsomes assessed as medium signal/noise ratio (S/N of 10 to 100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID308868Increase in PPARgamma2 gene expression in mouse 3T3L1 cells at 3 uM after 2 days relative to beta-actin mRNA expression2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
New type of anti-diabetic compounds from the processed leaves of Hydrangea macrophylla var. thunbergii (Hydrangeae Dulcis Folium).
AID162627Binding affinity against Peroxisome Proliferator activated receptor alpha (PPAR alpha); Not active1999Bioorganic & medicinal chemistry letters, Dec-06, Volume: 9, Issue:23
Synthesis and biological activity of a novel series of indole-derived PPARgamma agonists.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID189534The compound was tested in vivo for Antihyperglycemic activity in Zucker Diabetic fatty rats, activity is expressed as percent reduction of HbA1C.1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID717839Cytotoxicity against HEK293T cells assessed as decrease in cell viability at 12.5 uM after 24 hrs by trypan blue exclusion assay2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID136645Percent reduction in plasma triglyceride level was evaluated in mice at a dose of 200 mg/kg/day p.o. for 9 days1998Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9
Novel euglycemic and hypolipidemic agents: Part-2. Antioxidant moiety as structural motif.
AID252781Ability of compound to release intracellular calcium from Fluo-4 loaded 3T3 cells; + = Release2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation.
AID1680162Agonist activity at PPARalpha/PPARgamma in human AT-MSC cells assessed as upregulation of FABP4 mRNA at 1 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID712745Antitumor activity against human HT-29 cells assessed as inhibition of cell proliferation after 1 day by MTT assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
AID1680171Agonist activity at PPARalpha/PPARgamma in human AT-MSC cells assessed as upregulation of HMGCS2 mRNA at 1 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346800Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors)1998The Journal of pharmacology and experimental therapeutics, Feb, Volume: 284, Issue:2
Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma.
AID1346800Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors)1996Endocrinology, Oct, Volume: 137, Issue:10
Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.
AID1346800Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors)1998Journal of medicinal chemistry, Dec-03, Volume: 41, Issue:25
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
AID493017Wombat Data for BeliefDocking2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,789)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (0.11)18.7374
1990's392 (21.91)18.2507
2000's1056 (59.03)29.6817
2010's295 (16.49)24.3611
2020's44 (2.46)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index50.74 (24.57)
Research Supply Index7.60 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index80.30 (26.88)
Search Engine Supply Index1.99 (0.95)

This Compound (50.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials146 (7.86%)5.53%
Reviews189 (10.18%)6.00%
Case Studies46 (2.48%)4.05%
Observational0 (0.00%)0.25%
Other1,476 (79.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]